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Chapter 1: The Economic Effects of Medical Innovations: Vioxx and Labor Supply 
 
Despite dramatic improvements in medical technology over time, comparatively little 
attention has been paid to the effect of these innovations on economic outcomes.  This study 
uses seven overlapping panels of the Medical Expenditure Panel Survey to estimate the labor 
supply effects of Vioxx—a selective non-steroidal anti-inflammatory drug intended for 
individuals with chronic pain.  Fixed effect estimates analyzing the effect of individuals 
choosing to start and stop taking Vioxx indicates that use of the drug is associated with 
greater labor force participation.  This paper also exploits the removal of Vioxx from the 
market in 2004 as an exogenous source of variation in utilization.  Both methods show that 
Vioxx use is associated with statistically and economically significant increases in the labor 
supply of near elderly individuals with joint conditions.  An effect is also found for usual 
weekly hours worked. There is no labor supply effect for other expensive medications used 
for chronic conditions, suggesting that a desire to work in order to obtain employer-provided 
health insurance is not driving the estimated effect of Vioxx.  These results suggest a role for 
improving medical technology in explaining recent increases in the labor force participation 
rate of older workers. 
 
Chapter 2: The Effect of In-Utero Conditions on Long Term Health: Evidence  
      from the 1918 Spanish Flu Pandemic 
 
The fetal origins hypothesis posits that in-utero stress increases the incidence of chronic 
conditions later in life. Utilizing 21 years of National Health Interview Survey data, this study 
estimates the health effect of in-utero exposure to the 1918 Spanish Flu pandemic. Exploiting 
the fact that people were exposed to the flu at different points during fetal development, the 
model tests precise predictions from the medical literature about when exposure to in utero 
insults should damage organs later in life.  The pattern of results demonstrates the necessity 
of using a short duration event as a source of variation in fetal conditions and helps explain 
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Health care has become an essential sector of the American economy and 
currently accounts for approximately 16 percent of gross domestic product.  As 
expenditures in this sector continue to grow, government policies and regulation must 
adapt to the ever changing environment.  While public health professionals and 
medical doctors are obviously a key component in developing these new policies, 
economists have also increasingly played an important role.  This dissertation 
contributes to the body of knowledge in health economics in that it considers two 
examples where a broader understanding of the causes and consequences of particular 
events or innovations and their effects on people’s health will hopefully lead to 
improved policy decisions in the future.   
First, I estimate the economic, as opposed to solely health related benefits of 
medical innovations.  Knowledge about the full scope of benefits from these newly 
developed technologies is critical to effective policymaking. In the second chapter, I 
estimate the effect of in-utero conditions on the likelihood of developing chronic 
conditions in later life.  Together, these two chapters provide information that is 
useful for health policy professionals and show that economic analysis can help 
answer important questions in this field.  
The first chapter of this dissertation focuses on estimating the economic 
benefits of Vioxx, an innovative anti-inflammatory medication targeted at individuals 
with arthritis and other conditions requiring the consistent use of pain medication.  
Specifically, I focus on the effect of Vioxx on the ability of sick individuals to 




efficacy of a medication such as Vioxx whose primary endpoint—decreased pain—is 
difficult to measure in a clinical trial setting.  
Vioxx belongs to a family of drugs known as COX-2 inhibitors.  These 
medications are selective non-steroidal anti-inflammatory drugs (NSAIDs).  They 
were an improvement over the previous non-selective NSAIDs, which greatly 
increased the likelihood of gastro-intestinal bleeding (it is estimated that 16,500 
people a year die from NSAID related gastro-intestinal bleeding).  Unfortunately, 
after Vioxx’s release, subsequent clinical trial data found that the increased safety 
with respect to gastro-intestinal side effects came at the expense of a statistically 
significant increase in the risk of negative cardiac events.  As a result, Vioxx was 
removed from the global market in 2004.  At this time, Vioxx was on the top ten 
selling drugs in the global market.  This represented the largest voluntary recall of a 
prescription medication in United States history. 
In this chapter, I use the Medical Expenditure Panel Survey (MEPS) to 
estimate the effect of the use of Vioxx on labor force participation.  Due to the panel 
nature of the MEPS survey, I am able to control for individual-level time-invariant 
differences in the probability of working.  Such differences would likely bias any 
cross sectional estimates of the effect of Vioxx on labor supply.  I find statistically 
and economically significant increases in the probability of working for near elderly 
and elderly men with joint conditions taking Vioxx.  I find no effect for women. This 
is likely a result of the fact that few women in this age group are employed in 
occupations requiring physical labor—occupations with a high disutility of work for 




While the panel data estimates control for fixed differences between people 
over time, they are unable to control for time-varying factors that may affect both 
Vioxx use and labor supply.  Therefore, I also exploit the removal of Vioxx from the 
global market as an exogenous source of variation in the utilization of the drug.  
Instrumenting for Vioxx use using the removal of the drug from the market finds a 
large and statistically significant effect of Vioxx use on labor supply.  
Overall, these results show that the use of Vioxx increased the labor supply of 
near elderly individuals with joint conditions.  These economic benefits demonstrate a 
clear benefit in terms of an increased ability to participate in the labor force.  Similar 
benefits are not found for Celebrex—another popular COX-2 inhibitor.  There is a 
good deal of debate in the medical literature about the relative efficacy of these 
medications.  The results concerning labor supply in this chapter suggest that the 
economic benefits may be a useful additional quantitative metric for evaluating the 
relative efficacy of quality of life medications.   
Accurately quantifying the benefits of medical innovations can provide 
important information for the ongoing discussion concerning the rising levels of 
medical spending.  Increasing expenditures have caused national health services in 
countries around the globe to attempt to measure the cost effectiveness of new 
technologies.  There are growing calls for the United States government to do the 
same.  Even without explicit cost effectiveness policies, in regulating pharmaceuticals 
policymakers are forced to weigh the costs and benefits of newly developed 
technologies.  In order to accurately accomplish these evaluations, it is critical to 




system is increasingly focused on improving the quality of life by treating the 
symptoms of chronic conditions, and not solely extending the length of an 
individual’s life.  Therefore, an increasing portion of the benefits from these 
medications will likely affect an individual’s economic outcomes   In addition, 
understanding the economic benefits of these medications can better assist our 
understanding of the ability of the elderly and other individuals with chronic 
conditions to participate in the labor force.  This can have non-trivial consequences 
for both Social Security and the Social Security Disability Insurance programs.   
The second chapter of this dissertation estimates the effect of fetal stress on 
the development of later life health conditions.  It is estimated that approximately 75 
percent of United States health spending is aimed at treating chronic conditions.  This 
has led many policymakers to support plans aimed at preventive medicine.   
Effectively designing these programs, however, requires knowledge about the root 
causes of these expensive conditions. 
For several decades now, the medical literature has noted a connection 
between in-utero conditions later life health.  Formally, this connection is described 
as the fetal origins hypothesis (although it is also commonly referred to as the “Barker 
Hypothesis” in deference to David J.P. Barker—one of the first researchers to identify 
the connection).  A wide variety of animal experiments have shown that nutrient 
deprivation and other stress in-utero is causally connected to later life organ failure.  
Identifying this causal effect in humans, however, has proven far more difficult.  This 
should perhaps not be surprising as individuals who experience in-utero stress often 




these two conditions on the likelihood of developing chronic conditions in 
observational studies is difficult.  
 Identifying the effect in humans would most easily be done through a random 
assignment experiment.  For a variety of clear and valid ethical reasons this is 
unlikely to occur.  Therefore, researchers have turned to other plausibly exogenous 
sources of variation in fetal conditions.  For example, individuals have used in-utero 
stress caused by the Chinese and Dutch famines as well as the Siege of Leningrad 
during World War II to estimate the effect of fetal conditions on later life health.  
Estimates using these events have returned mixed evidence regarding the fetal origins 
hypothesis.  As is discussed in this chapter, it is likely that the inability to find later 
life health effects is due in part to the long length of the previous events used as 
sources of variation. 
The medical literature reports that the timing of in-utero stress should generate 
different conditions in later years.  For example, the kidneys primarily develop during 
the later months of development and, therefore, stress during the last trimester should 
be more likely to result in kidney disorders.  Conversely, stress during the first 
months of in-utero development will likely have little effect on long term kidney 
health.  The difficulty presented by long duration events as a source of exogenous 
variation is the complexity in pinpointing specific windows of fetal stress which 
generates a large downward bias in the estimated effect of fetal stress for any 
particular condition.   
The source of variation utilized in this chapter is the peak of the 1918 global 




flu variant.  As a result, individuals who were in-utero during the pandemic suffered 
dramatic decreases in fetal health. Douglas Almond (2006) was the first author in the 
economics literature to use this as a source of variation in fetal conditions.  His paper, 
however, estimated the effect of fetal stress on primarily non-health outcomes.  
Almond and Mazmunder (2005) estimated the effect of in-utero flu exposure on 
health outcomes.  My chapter expands upon this earlier work by using a larger sample 
size and explicitly attempting to connect the results to the predictions of the medical 
literature. In total, my results show that the timing of exposure to fetal stress is 
critically important in predicting later life health outcomes.  Individuals exposed to 
the peak of the 1918 flu pandemic during different trimesters are more likely to 
develop conditions related to organs that were primarily developing during that time 
period.   
In addition to providing more evidence in support of the fetal origins 
hypothesis and demonstrating the important of a short duration event as a source of 
variation, I believe that these results show the importance of more cohesive health 
and welfare policy.  The fact that chronic conditions (which are often paid for by 
Medicare and Medicaid) may have their roots in-utero suggests that health policies 
aimed at decreasing medical expenditures and increasing overall health should be 
integrated throughout (and possibly before) an individual’s lifetime.  For example, 
later life health outcomes may justify increased funding for prenatal programs or 





Chapter 1: The Economic Effects of Medical Innovations: Vioxx and 
Labor Supply 
 
The percentage of the population participating in the labor force has remained 
relatively constant over the last two decades.  Over this period, the labor force 
participation rate for working age individuals only increased by 0.3 percentage 
points—from 65.7 to 66 percent.  Examining labor force participation for different 
age groups, however, reveals that there has been a dramatic increase among older 
individuals over the same period.  Figure 1 contains the change in labor supply 
between 1987 and 2007 for males and females by age.  Over the last two decades, 
males aged 60 and older increased their labor supply while younger individuals 
worked at a lower rate.  Women at most ages worked more in 2007 than in 1987, but 
the increase was far larger at older ages.   
While there are many factors that can influence changes in labor supply, a 
primary determinant is a persons’ physical and mental health.  Economists have 
consistently found that poor health is causally related to lower levels of labor supply 
(Currie and Madrian, 1999). Researchers have also found that the number of 
individuals with chronic conditions has grown and the likelihood of being diagnosed 
with such a condition increases with age (Wu and Green, 2000; Hoffman and 
Schwartz, 2008).  Based on these facts, it would be reasonable to expect that, holding 
age constant, the labor force participation of elderly individuals in recent years would 
remain constant, or even decrease.   
Although the explanations for the recent rise in labor force participation 




is the large number of medical innovations during the time period. Over the last two 
decades health spending has increased dramatically.  Spending on health services in 
the United States now equals 16 percent of gross domestic product.  Newhouse 
(1992) found that improvements in medical technology are a primary cause of 
increases in health care spending.  Technology driven cost increases have been 
particularly apparent in the case of pharmaceuticals.  From 1980-2005, the percentage 
of medical spending on pharmaceuticals doubled (Caitlin et al., 2007).  In recent 
years, the majority of this increased spending came from higher usage and new drugs 
as opposed to simply increased prices on existing drugs (Smith, 2004).  Looking at 
specific chronic conditions, in 2001 Americans spent 533% more in inflation adjusted 
dollars on drugs to treat diabetes and 374% more on drugs to treat arthritis than they 
did in 1987 (Stagnitti and Pancholi, 2004).   
Little is known about the presence or the magnitude of the economic effects of 
the dramatic increases in health spending, utilization of medical services, and the 
introduction of innovations.  Hirth, Chernew, Turene and Pauly et al. (2003) noted 
this fact when they said, “[e]ven papers that have used instrumental variables 
techniques to address the endogeneity of health have not analyzed how the choice 
among available medical treatments or the change in available treatments over time 
can mediate the effects of health on outcomes such as labor force participation, 
wages, earnings, and hours” (Hirth et al., 2003: 168).   
The authors who have estimated the relationship between medical innovations 
and economic outcomes have primarily focused on developing countries or on mental 




treatments on improving labor supply in sub-Saharan Africa (Thirumuthy et. al., 
2008).  In the developed world, authors have evaluated the role of increased mental 
health treatment on labor market outcomes (Berndt, 2000; Berndt et al., 1998; 
Thimbie et al., 2006).  These studies have used data from clinical trials and found that 
increased treatment for mental health conditions such as depression increased at-work 
productivity and participation.   
This study attempts to increase understanding in this area by examining the 
relationship between the introduction of a widely used medical innovation and the 
ability of individuals with chronic physical conditions to supply labor.  I focus on the 
release and subsequent removal from the market of the anti-inflammatory medication 
Vioxx.  Developed by Merck, Vioxx was approved for sale by the FDA in 1999. It 
was intended for “relief of the signs and symptoms of osteoarthritis, the management 
of acute pain, and the treatment of primary dymenorrhea” (Food and Drug 
Administration, 1999).  Patients receiving these prescriptions primarily report the 
presence of joint and back conditions.1  As a result, these individuals often require the 
continual use of anti-inflammatory medications in order to perform common tasks.  
With respect to gastrointestinal side effects, Vioxx was believed to be safer for 
everyday use than previously existing medications.  The drug’s initial sales were 
strong and by 2001 it was already the 11th highest selling drug in the world with over 
$2.5 billion in worldwide sales.  In 2004, a clinical trial reported an elevated cardiac 
risk for individuals taking Vioxx.  As a result of this study (and previous indications 
of potential negative cardiac effects) Merck issued a world-wide recall of the drug in 
                                                 





September, 2004—the largest voluntary recall of a prescription medication in United 
States history. 
The introduction and surprising removal of Vioxx from the market provides a 
rare opportunity to estimate the effect of medical innovations on economic outcomes. 
Vioxx was intended for conditions such as arthritis whose primary symptoms (pain 
and swelling) can be addressed by the use of effective analgesics.  According to the 
Centers for Disease Control (CDC), 30 percent of individuals with arthritis report 
work limitations from the condition (Lorig, 2007).  For these individuals and others 
with chronic pain, COX-2 inhibitors such as Vioxx represented a new solution for 
pain relief. 2   
Initially, I use seven overlapping panels of the Medical Expenditure Panel 
Survey (MEPS) from 1998-2004 to estimate the effect of Vioxx prescriptions on 
labor supply.  The MEPS provides detailed information on the socio-economic 
characteristics and prescription medicine habits of individuals over time.  Exploiting 
the panel nature of this data, I estimate the labor supply effect of individuals choosing 
to start and stop taking Vioxx while controlling for time-invariant differences in labor 
supply across people.  I find a statistically and economically significant increase in 
the probability of working for males taking Vioxx.  For example, Vioxx use in the 
previous period is associated with a nearly 12 percent increase in the probability of 
working for males aged 55-61 with joint conditions.  This effect is stronger for men in 
physical occupations.  Examining the effect on hours worked, Vioxx use is found to 
have a positive and statistically significant increase on usual hours worked.  Further 
                                                 
2 Cox-2 inhibitors were sold under several brand-names.  The largest were Vioxx, Celebrex, and 
Bextra.  In 2002, global sales of Celebrex were $3 billion, those of Vioxx were $2.5 billion, and those 




investigation finds, however, that the increase in hours is likely a result of increased 
participation and not adjustment along the intensive margin.  Falsification tests using 
other expensive medications find no similar relationship for these drugs suggesting 
that individuals are not working in order to obtain employer provided health 
insurance.  No effect is found for female labor supply. 
One concern about these fixed-effects results, and of any other observational 
studies examining the effects of pharmaceuticals, is potential endogeneity in the 
decision to start or stop taking the medication.  While the use of panel data methods 
limits concerns about time-invariant factors biasing my estimates, unobservable time-
varying factors could potentially bias the estimated causal effect of Vioxx on labor 
supply.  The removal of Vioxx from the market provides an unusual source of 
exogenous variation in the use of a widely prescribed pharmaceutical.   
Vioxx represented the largest voluntary recall of a prescription drug in 
American history.  While it was available, there were over 80 million prescriptions 
written for Vioxx and in 2004—the year of withdrawal—approximately 1.3 million 
Americans were taking the drug (Kaufman, 2004).  An analysis of employer health 
insurance claims found that by 2006, only 16 percent of previous Vioxx users were 
using Celebrex—another widely prescribed COX-2 inhibitor.  One quarter claimed no 
prescription pain reliever use at all (Huse and Marder, 2007).  This suggests that the 
removal of Vioxx from the market represented the end of effective pain medication 
for a substantial portion of the population. The removal decision was unexpected by 
the general public.  The day following the removal announcement, Merck’s stock 




anticipated, it is reasonable to assume that post-removal changes in utilization should 
be unrelated to other factors correlated with changes in economic outcomes.  I 
implement an instrumental variables strategy exploiting this exogenous change and 
find statistically and economically significant effects of Vioxx on labor supply.   
Accounting for the economic benefits of medications can have important 
implications for health policy—particularly the regulation of pharmaceuticals.  New 
drugs are increasingly aimed at increasing the quality of life rather than simply its 
length (Bren, 2007). As a result, economic outcomes will potentially comprise a 
larger portion of the expected benefits profile.        
What is Vioxx? 
 Vioxx is a member of the COX-2 inhibitors family of pain relievers.  These 
drugs are broadly described as selective non-steroidal anti-inflammatory drugs 
(NSAID).  They work by blocking the cyclooxygenase-2 (COX-2) enzyme and are 
primarily intended for individuals with chronic conditions requiring a nearly 
continual use of anti-inflammatories.  Prior to the introduction of these medications, 
individuals with these conditions were limited to non-selective NSAIDs such as 
ibuprofen or naproxen that block both the COX-1 and COX-2 enzymes.  One function 
of the COX-1 enzyme is protecting the stomach lining.  As a result, non-selective 
NSAIDs increase the chance of gastro-intestinal (GI) bleeding—making them 
unsuitable for continual use in many patients. Each year, an estimated 16,500 
individuals die from non-selective NSAID-related gastrointestinal complications.  
This amounts to 1 death for every 1,200 patients taking these drugs for two months or 




individuals susceptible to this bleeding were unable to take existing NSAIDs and 
often had to live with chronic pain. 
 COX-2 inhibitors represented an entirely new technology and as a result they 
were very popular.  In a post-marketing survey of more than 80,000 patients, 
approximately 85 percent of respondents reported an improved quality of life from 
Vioxx.  These respondents also found the once-daily regime of Vioxx simpler than 
their previous pain treatments (Zacher and Schattenkirchner, 2004).  Examining 
medical claims data from 19 affiliated managed care plans covering 300,000 
physicians and more than 4 million enrollees, Harley and Wagner (2003) found that 
users of COX-2 inhibitors were approximately 57 percent less likely to discontinue 
medication and 60 percent less likely to switch medications than were users of non-
selective NSAIDs.  This persistence in use is an often-used measure of patient 
satisfaction and side effects (Chan and Hamilton, 2006; Hasford et al. 2002; Dusing, 
2001).  In a study of individuals treated first with non-selective NSAIDs and 
subsequently with Vioxx, patients reported better satisfaction and health status while 
taking Vioxx. These patients also had a lower rate of treatment discontinuation due to 
lack of efficacy or adverse GI events (Arboleya et al., 2003).  Schmidt et al. (2004) 
found that “the efficacy of rofecoxib [Vioxx] in osteoarthritis in various clinical 
studies is comparable to that of conventional NSAIDs but the incidence of adverse GI 
events with rofecoxib is significantly lower than with nonselective NSAIDs” 
(Schmidt et al., 2004: 194).  Mamdani et al. (2002) found that “relative to rofecoxib, 
non-selective NSAID users were at significantly higher risk of upper gastrointestinal 




use of coxibs [COX-2 inhibitors] to treat OA [osteoarthritis] and RA [rheumatoid 
arthritis] is recommended as first-line therapy when symptoms of pain and 
inflammation are present in patients vulnerable to potential NSAID-associated GI 
toxicity” (Schnitzer and Hochberg, 2003: 20).  
 The underlying supposition of this analysis is that the use of Vioxx decreases 
the negative health effects of chronic conditions, and as a result the disutility of work, 
to the point that individuals are able to increase their labor supply.  Therefore, at a 
minimum, the use of this drug should improve the self-reported health status of 
recipients.  Examining MEPS respondents who reported Vioxx use provides 
information about the effect of Vioxx on poor health.  The percentage of respondents 
reporting poor health increases by nearly 20 percent from the period before first 
Vioxx usage to the period where Vioxx is first reported.3  This suggests that 
worsening health causes individuals to fill a prescription for Vioxx.  In the period 
immediately following the first use of Vioxx, the percentage of these individuals 
reporting poor health decreases by approximately 7 percent.  While by no means 
conclusive, this provides suggestive evidence of a potential effect of Vioxx on the 
ability of individuals to complete daily tasks such as working.  
Prior to Vioxx’s introduction to the market, a potential for increased cardiac 
risks was noted in the Vioxx GI Outcomes Research (VIGOR) study.  VIGOR 
revealed a four fold increase in cardiac events for patients taking Vioxx compared to 
those taking naproxen (Bombadier et al., 2001).  Concerns later developed about 
decisions made during the conduct of that study with respect to removing some 
                                                 
3 Individuals are classified as reporting poor health if the report being in “fair” or “poor” health on a 5 




individuals in the treatment group who suffered negative cardiac events.  Following 
Vioxx’s introduction, a study estimating the effect of Vioxx on reducing colon 
polyps—the Adenomatous Polyp Prevention With Vioxx (APPROVe) study—
confirmed previous findings that the drug’s benefits in terms of patient satisfaction 
and decreased intestinal toxicity came at the apparent expense of an increased relative 
risk of cardiac events (Bresalier et al., 2005). The results of the APPROVe study 
combined with other studies and the potential errors in the VIGOR study caused 
Merck to voluntarily remove Vioxx from the market on September 30, 2004.   
There is mixed evidence regarding the relative efficacy of Vioxx compared to 
other COX-2 inhibitors such as Celebrex and traditional non-selective NSAIDs such 
as ibuprofen and naproxen.  Smugar et al. (2006) reported the results of two clinical 
trials, one of which found that pain relieving benefits of Vioxx were superior to 
Celebrex and another which found they were similarly efficacious.  Several studies 
have found that the onset of pain relief was faster for Vioxx than Celebrex (Schnitzer 
et al., 2005; Battisiti et al., 2004).  Examining the economic outcomes of Celebrex 
compared to Vioxx may provide more information about the relative efficacy of the 
medications.  Differences between clinical trials measures of efficacy and the 
observed economic effects of medications may serve as further evidence of the 
importance of considering non-health outcomes in the benefits profile of quality of 
life drugs.4    
Since its removal, anecdotal evidence abounds of consumers pushing for a 
reversal in this decision in order to regain access to the medication (Payne, 2004; 
                                                 
4 This may be due to the fact that the benefits profile of these medications normally rely on subjective 




Mondics, 2005).  In a telephone survey of elderly arthritics, Tannenbaum (2006) 
found that despite the acknowledged cardiac risk, 18 percent would still take Vioxx if 
it was available.  This is despite the fact that the average respondent in this survey 
overestimated the risk of heart attack or stroke by more than 50 percent.  
 
Health and Labor Supply 
The effect of health on labor supply has long been studied in economics.  
Authors have estimated the effect of chronic conditions, health shocks, and the health 
of an individual’s spouse or dependents on a variety of economic outcomes.  Currie 
and Madrian (1999) provided a comprehensive review of the estimated effect of 
health on labor supply.  Overall, they reported that economists have found a direct 
relationship between health and labor force participation.5  This exists across several 
subgroups.  For example, in a more recent study, Haider and Loughran (2001) used 
data from the Assets and Health Dynamics of the Oldest-Old (AHEAD) and found 
that negative health shocks, represented by declining health status or an increasing 
number of difficulties with activities of daily living, were a primary cause of elderly 
individuals exiting the labor force.   
Other authors have specifically examined the effect of arthritis on labor 
supply. Bartel and Taubmman (1979) was one of the first studies to examine the 
                                                 
5 This review also contains very detailed discussions of important issues related to health and labor 
supply concerning such factors as measuring health and the endogeneity of self-reported health status 
and conditions.  While my study does rely on patient reported health conditions, the concerns for 
endogeneity of these responses are limited in the case for several reasons.  First, the questions are 
related to specific conditions and not simply a coarse measure of self-reported health status.  Second, 
the primary purpose of the MEPS is for the discussion of medical conditions, and not labor market 
outcomes, potentially limiting the desire to “justify” lack of labor force participation.  Furthermore, 
this study concerns itself with reported prescription medications which are unlikely to be endogenous 




effect of specific conditions (rather than self reported health status) on labor supply.  
Of interest to this analysis, the authors found that the presence of arthritis was 
associated with a decrease in the probability of working and on wages.  Similarly, 
Mitchell and Burkhauser (1990) found that arthritis lowers the wages of affected 
individuals both through a direct effect and as an indirect effect of fewer hours 
worked.  Mitchell (1991) found that worsening health status is the primary reason for 
labor force exits among men with arthritis. 
Examining the health of union veterans of the civil war in 1900 and 
participants in the National Health Interview Survey from 1985-1991, Costa (1996) 
found that while BMI—an indicator of health status—was a primary determinant in 
labor force status in both periods, this connection has weakened over time.  Costa 
(1998) stated “health now appears to be less important to the labor force decision.  
Although the relation between BMI and the risk of labor force non-participation in 
1900 was remarkably similar to that in 1985-1991, men in 1900 were much more 
responsive to changes in health than they are now” (Costa, 1998: 82).  Costa cited 
many possible reasons for this change, including a difference in the relationship 
between chronic conditions and BMI, the decreasing physical demands of 
employment, and the shortening of the workday.  
 The central question of my study examines the relatively unexplored topic of 
the role of improvements in medical technology on the relationship between chronic 
conditions and labor market outcomes.  This is a topic of great importance given both 
the large number of advancements in the medical field and the rapid aging of the 




chronic conditions.  Studies addressing this topic have thus far primarily focused on 
the developing world.  For example, economists have examined the spread of AIDS 
across Africa combined with the development of anti-retroviral (ARV) treatments to 
study the relationship between medical innovations and economic outcomes in the 
developing world (Thirumuthy et al. 2005).  
 Studies documenting the connection between medical technology, disease 
survival, and labor supply in the developed world are sparser.  Lichtenberg (2002) 
estimated the effect of aggregate changes in drug utilization on labor supply.  
Lichtenberg used condition-level data on the utilization of medical services in an 
attempt to overcome an omitted variable bias caused by an inability to control for 
condition severity at the individual level.  He found that for conditions with above 
average changes in drug utilization there were above average changes in labor supply.  
Lichtenberg was unable, however, to control for unobservable factors that may have 
caused the above normal usage of medical technology at the condition level. The 
failure to utilize any exogenous change in drug utilization leaves open a concern 
about endogeneity in the changes in drug utilization.  The few studies in the 
developed world that have utilized exogenous variation in drug usage to estimate 
economic benefits have focused almost entirely on mental health disorders.  Using 
data primarily from clinical trials, authors have found that increased use of mental 
health treatment increases both labor supply and at work performance (Timbe et al., 
2006; Berndt et al., 1998; and Berndt et al., 2000). 
As the American labor force continues to age, a greater portion of potential 




many of which cause debilitating pain.  One of the most prevalent conditions causing 
everyday pain, particularly among the elderly and near elderly, is arthritis—a disease 
characterized by pain and stiffness in the joints that often reduces physical function 
and mobility.  According to the Center for Disease Control, an estimated 46 million 
people in United States have some form of arthritis.  In total, 5 percent of the 
population and 30 percent of the arthritis population report work limitations resulting 
from the disease (Lorig, 2007).  Yelin (1995) reported that disability rates for 
individuals with musculoskeletal conditions range from 38 to 72 percent.  Pain 
relievers such as COX-2 inhibitors have been shown to increase mobility and 
functioning, allowing individuals to participate in everyday activities while 
potentially reducing dangerous side effects.   
  The presence of a chronic painful condition alters the typical labor supply 
decision of an individual.  While most potential workers receive disutility from effort, 
for individuals with painful joint conditions the disutility from even a limited amount 
of work could be too great to allow the person to participate in the labor force.  
Consider a simple motivating model with an individual possessing a utility function 
of the form:  
iiiiiiiiii hlTtscrlTglTwvu =+−−−= ..),,())(*(   (3) 
Where Ti is an individual time endowment, li is an individuals hours of leisure, hi is 
the number of hours worked, w is the wage, v() is the utility from wage income, and 
g() is the disutility from effort.  Equation (3) easily simplifies to: 




where disutility of effort is a function of hours worked, the presence of a chronic 
condition (ci), and the efficacy of existing medical treatments (ri).  Disutility is an 
increasing function of hours worked and the presence of chronic conditions and a 
decreasing function of available medical technology.  For simplicity, I assume the 
presence of a chronic condition is a binary variable equal to 1 if a painful chronic 
condition exists.  Similarly, the efficacy of existing medical treatments is a binary 
variable equal to 1 if existing medical treatments are effective for the individual.6  
There are three states of the world that are of concern for each individual: not sick, 
sick with effective medical treatment, and sick with ineffective medical treatment.7  























  (5) 
Solving the individual’s maximization problem reveals that at each wage an 
individual chooses hours such that: 

















     (6)
  
Equations (5) and (6) provide the result that individuals who are not sick will work 
more hours than those that are sick, and those with access to effective medication will 
                                                 
6 The underlying results of this model carry through to the case of more refined measures of both 
treatment efficacy and condition status. 




work more hours than those without.8  For some individuals, the disutility of work in 
the presence of a chronic condition without effective medical technology is large 
enough that for all offered wages their optimal hours worked is zero. 
This study hypothesizes that the release of Vioxx represented the introduction 
of an effective medical technology for a portion of the people with chronic conditions 
causing pain.9  This is expected to increase the labor supply for individuals with 
chronic conditions.  This increase could occur either in the form of more hours or 
greater labor force participation. 
Figure 2 provides suggestive evidence of this correlation between Vioxx and 
labor force participation for those with arthritis.  The graph contains data from the 
Medical Expenditure Panel Survey (MEPS).  The dotted line represents the rate of 
Vioxx prescriptions for individuals with joint conditions in the MEPS and the solid 
line represents the labor force participation rate for the same respondents.  The graph 
provides suggestive evidence that labor force participation among those with joint 
conditions is correlated with the use of Vioxx. 
 
Data 
The data for this study come from the Medical Expenditure Panel Survey 
(MEPS).  The MEPS is a series of surveys administered since 1996 by the Agency for 
Healthcare Quality Research and the National Center for Health Statistics.  There are 
                                                 
8 For the purposes of this simple model I am ignoring the demand side of the equation.  It is likely, 
however, that the presence of both chronic conditions and effective pain medication would also change 
an individual’s marginal product of labor and offered wage.  
9 This could be the result of an individual being unable to take existing medication due to 




three components of the survey, completed by households, medical providers, and 
insurance companies.  This study uses the household component of the MEPS, which 
is comprised of a sample drawn from the previous year’s National Health Interview 
Survey (NHIS) respondents.  Individuals are asked questions over a series of 5 rounds 
detailing two years of medical expenditures and services utilization.  Each year of the 
MEPS contains respondents from two overlapping panels.   
The MEPS full year consolidated data file (CDF) contains socio-demographic 
information for respondents including age, sex, race, and basic economic 
characteristics.  Individuals are asked about their labor force participation status 
during each round of the MEPS.  For this study, respondents are classified as working 
if they report being employed at the time of interview or at any time during the MEPS 
round.   
This study also uses data from the MEPS prescribed medicines file which 
contains data on the prescription habits of all respondents.  The unit of observation is 
the individual prescription, and information is also collected concerning medical 
conditions directly associated with the prescription.  In the time period under 
consideration, approximately 40 percent of individuals do not report receiving 
prescriptions.  Data from the prescribed medicines files can be linked to the MEPS 
CDF. 
 Data from the MEPS medical condition file is also utilized in this study. The 
unit of observation in this file is a reported medical condition for a respondent.  




and treatment attempts.10  In this sample, approximately 20 percent of MEPS 
respondents report no medical conditions throughout the year.  Using the unique 
identifier, information from the medical conditions file can be linked to both the 
prescribed medicines file and the full year CDF.   
In total, the combined sample for this analysis has 108,048 distinct individuals 
interviewed a maximum of 5 times.  This creates an unbalanced panel of 512,788 
observations.  The MEPS is uniquely able to provide information on the question of 
interest because it is the only dataset that contains data on socio-economic status, 
detailed prescription medicine activity, and medical conditions.  The National Health 
Interview Survey (NHIS), from which the MEPS is drawn, has the advantage of a 
larger sample size then the MEPS, but it does not contain information on 
prescriptions.  Similarly, the Center for Disease Control’s Behavioral Risk Factor 
Surveillance System (BRFSS) contains data on arthritis status but does not have 
information on prescription status.   
 
Characteristics of Vioxx Recipients 
Table 1 contains data on the ICD-9 codes reported by individuals who report a 
Vioxx prescription during their time in the MEPS.  Over 40 percent of individuals 
using Vioxx report “other and unspecified arthropathies” in at least one interview.  
An arthropathy is a disease of the joint that includes, but is not limited too, arthritis.  
An additional 20 percent of Vioxx patients report the presence of back disorders. 
                                                 
10 The International Statistical Classification of Diseases and Related Health Problems (ICD) codes are 




Arthropathies in general, and arthritis in particular, are painful chronic 
conditions that limit the daily activity of afflicted individuals.  Figure 4 shows the 
percentage of individuals reporting a joint condition by age.  The percentage of 
individuals with these conditions increases with age.  Nearly 65 percent of MEPS 
respondents in the sample reporting an arthropathy during at least one round are 55 
years of age or older.   
The presence of an arthropathy is a limiting factor in completing everyday 
activities.  Examining individuals in the MEPS by age and arthropathy status shows 
that in each age range a higher percentage of individuals with an arthropathy report an 
“activity limitation.” These limitations include work limitations, school limitations, or 
house limitations as defined in the MEPS.11  For example, only 14 percent of 55 year 
old respondents without an arthropathy report limitations compared to over 40 
percent of people with an arthropathy. The self-reported health status of individuals 
afflicted by these conditions reflects these limitations.   
On average, Vioxx recipients are similar to individuals of approximately the 
same age in the MEPS.  Table 2 compares the demographics of individuals in the 
MEPS who have filled at least one Vioxx prescription and all respondents between 
the ages of 55 and 65.  In general, the groups were similar in education and racial 
make-up.  Women make up 67 percent of Vioxx recipients, but only 53 percent of 
similarly aged MEPS respondents.  This should not be surprising since arthritis is 
more prevalent among women (Lorig, 2007).  On a 5 point scale, with higher 
numbers representing worse health, the average self-reported health status of Vioxx 
                                                 
11 Individuals are classified as limited if they report difficulty completed tasks such as lifting 10 




recipients is 2.99 compared to 2.61 for non-recipients.  Recipients are also less likely 
to report they are working.  Table 3 contains descriptive statistics for individuals that 
report a chronic joint condition during at least one round of the MEPS.  Individuals 
are categorized by whether they also report filling a prescription for Vioxx during any 
reference period.  Individuals taking Vioxx are older but roughly similar in racial 
make-up.  Over 68 percent of the Vioxx recipients are women compared to nearly 62 
percent of the non-Vioxx individuals with joint conditions.12  Vioxx recipients have a 
worse reported health status but reported working at nearly the same rate as those not 
taking Vioxx.  Overall, Vioxx recipients appear similar to all individuals with joint 
conditions.  
Figure 3 contains the percentage of MEPS respondents over 40 who report 
any prescriptions that received a Vioxx or Celebrex prescription by year.  Following 
its introduction in 1999, Vioxx use quickly rose until prescriptions peaked in 2001 at 
slightly more than 4 percent of this group. In that year, the FDA held an advisory 
meeting on the results of the VIGOR study and published data on all cardiac events 
related to Vioxx in the study, including those that were initially withheld (Prakash 
and Valentine, 2007).  This resulted in a warning label on Vioxx in April 2002.  
Graphical evidence suggests that this warning did decrease the attractiveness of the 
medication, as the percentage of Vioxx prescriptions fell each year following the 
warning until it was pulled from the market in late 2004.  It can also be seen that the 
warnings for Vioxx appeared to affect the prescribing patterns of Celebrex—albeit to 
                                                 
12 Dominick et al. (2003) found that women with arthritis are more likely to be prescribed NSAIDs, 




a lesser extent.  This may be the result of a lack of clarity at the time whether the 
negative cardiac effects of Vioxx were a drug or class specific effect.   
 
Estimation Strategy 
A naïve approach to estimating the effect of Vioxx on labor supply might examine the 
cross-sectional relationship between labor supply and Vioxx usage.  This would 
involve estimating an ordinary least squares (OLS) model of the following form: 
 
iiiiiii CONDVIOXXVIOXXXAGEfWORKING νββδγα +++++= *)( 21    (7) 
 
in which WORKINGi is a binary variable equal to 1 if individual i reports working; 
Xi is a vector of time invariant socio-demographic factors; f(AGEi) is a high order 
polynomial to control for the effects of aging, VIOXXi is a binary variable equal to 1 
if an individual reports a Vioxx prescription during the reference period, CONDi is a 
dummy variable for individuals that report conditions causing chronic pain, and iν  is 
an idiosyncratic error term.  The coefficients of interest are the combination of 1β  
and 2β .  The linear combination of these two coefficients represents the increased 
probability of a Vioxx recipient with a chronic condition working.  In the empirical 
specifications below I will separately estimate the effect for chronic joint and back 
conditions—the most prevalent conditions for Vioxx users in Table 1.13  I will 
exclude traumatic injuries because these injuries could be the cause of an individual 
                                                 
13 Includes individuals who report “osteoarthritis,” “other and unspecified arthropathies,” or “other and 
unspecified disorders of joint,” (ICD-9 codes 715, 716, and 719) are coded as having a joint condition.  
Those reporting “intervertebral disc disorders,” “Other disorders of cervical region,” or “other and 




not working and their subsequent return to work may be the result of healing and not 
the palliative effects of Vioxx.  
The cross sectional specification is unlikely to provide a reliable estimate of 
the causal effect of Vioxx use on the probability of working.  This is due to the fact 
that there are potentially several unobserved variables that are also captured by the 
estimated coefficient.  Specifically, the error component in equation (7) could 
actually be of the form, iii εµν += , which includes an unobservable person specific 
effect and an idiosyncratic error term.   To the extent that this person specific effect is 
correlated with VIOXXi, any estimate of the medication’s effect on labor supply will 
be biased in an unknown direction.  For example, individuals who take Vioxx could 
also have a greater desire to work and as a result the estimate of Vioxx’s effect on 
labor supply could be biased upwards.   
The panel nature of the MEPS allows the use of a fixed-effect estimator to 
control for the time-invariant person-specific qualities such as an individual’s 
propensity to work.  Under the assumption that the omitted variables creating a bias 
in equation (7) are not time-varying, this procedure will consistently estimate the 
effect of Vioxx on labor supply.  In addition, multiple observations of an individual’s 
prescription activity over time allows for the consideration of the effect of Vioxx 
usage in previous periods on current period labor supply.  I allow for a lagged 




medications.  It may take some period of time before they realize the pain relieving 
effects of the medication and decide to reenter the labor force.14 
I implement a fixed-effects identification strategy to estimate the relationship 
between taking Vioxx in time period t or t-1 and working in time period t.  This 
estimation strategy will provide a consistent estimate of the effect of Vioxx under the 
assumption that there are no time-varying factors, other than the medication, affecting 
the labor supply decision of individuals with these chronic conditions that are also 
correlated with any of the explanatory variables.  















           (8) 
in which µi is a person-specific time invariant fixed effect, VIOXXit and VIOXXit-1 
are binary variables equal to 1 if an individual reports a Vioxx prescription during the 
current and subsequent period respectively,15 tπ  is a variable accounting for the 
MEPS round, itε is an idiosyncratic error term, and all other variables are defined as in 
equation (7).  Other potential factors affecting labor force participation such as race 
and sex are time invariant and their influence is captured by the person-specific fixed 
effect.  The first set of coefficients of interest are the combination of 1β and 3β  which, 
given the assumptions described above, represent the effect on the probability of 
                                                 
14 Choosing the way in which Vioxx’s lagged effect will be modeled requires balancing the number of 
lagged periods and the sample size.  In the MEPS, individuals are only observed for 5 periods.  Each 
lagged period requires limiting the sample by one reference period.  Equation (8) allows for a 
relatively large sample while still accounting for a potential lagged effect of Vioxx on labor supply.  
15 This specification defines Vioxx use as every period in which a prescription is reported.  Alternate 
specifications include focusing only on the first Vioxx prescription, or as every period after the first 
prescription is reported.  Specifications using either of these alternate definitions of Vioxx use return 




working during the period a Vioxx prescription is filled for individuals with chronic 
conditions.  A combination of 2β and 4β  provides the estimated effect for taking 
Vioxx in the previous period. The fixed effects regressions are weighted using MEPS 
longitudinal weights, although unweighted specifications return qualitatively similar 
results.  A similar specification using Celebrex prescriptions rather than Vioxx is also 
estimated in order to examine the relative efficacy of the two medications.   
A concern in any analysis of panel data is serial correlation in the error term.  
This is particularly true when the dependent variable is known to exhibit positive 
serial correlation, such as labor supply.  Failing to account for this serial correlation 
can bias the estimated standard errors and lead to incorrect inferences (Bertrand et al., 
2004). In the case of a large number of groups, Wooldridge (2003) states that this 
problem can be overcome by allowing for an arbitrary variance-covariance matrix 
accounting for within group correlation in the errors at the individual level.  
Though the fixed-effects estimation strategy does control for potentially time-
invariant unobservable factors, the binary nature of the dependent variable means this 
OLS specification may produce inaccurate estimates.  While the linear probability 
model often returns consistent estimates, and is preferable because the economic 
significance of its coefficients is easier to interpret, it can have difficulty returning 
consistent results under certain conditions.  This is particularly true when the mean of 
the dependent variable is close to either zero or one and the linear probability model 
fails to constrain the dependent variable to this unit interval.  While the labor supply 
rate in this case is not located at either extreme, I will also estimate a conditional logit 




probability model.  Chamberlain (1980) showed that estimating a logit model with 
individual fixed-effects will provide inconsistent parameter estimates.  This is due to 
the classic incidental parameters problem first discussed in Neyman and Scott (1948).  
To overcome this problem, Chamberlain suggested estimating a conditional fixed 
effects logit model.  This model uses variation in the pattern of observations in the 
dependent variable to predict the probability that a set of outcomes will occur.  For 
this reason, individuals who report all positive or negative outcomes for the 
dependent variable are discarded. Arellano and Honore (2001) showed that estimating 
a logit model on this restricted sample returns consistent estimates.  In this case, 
individuals who report either working or not working in all MEPS reference periods 
are discarded—greatly reducing the sample size.  
Regardless of the empirical specification, a concern for estimating the effect 
of Vioxx is identifying the group of individuals whose labor supply would likely be 
affected by chronic conditions requiring anti-inflammatories.16  Figure 4 contains 
individuals in the MEPS who report a chronic joint condition by age.  These 
conditions generally do not present themselves until later in life and as a result 
including a sample of all working age individuals may result in a diluted estimated 
treatment effect.  In order to ensure that a large number of individuals are affected by 
chronic conditions requiring Vioxx, I limit the lowest age range in the sample to 
individuals who are older than age 55.   
It is also important to identify an upper limit for the age range that takes into 
account the presence of social security and other retirement programs affecting the 
labor supply decision. Individuals who qualify for benefits can claim social security 
                                                 




early (at age 62) and receive a reduced benefit.  Economists have long noted a mass 
point of retirements at this age.  French (2005) analyzed the Panel Study of Income 
Dynamics (PSID) and found “work-hours and labour force participation decline 
sharply after age 55, and especially sharply at ages 62 and 65. These are exactly the 
ages at which Social Security, pensions, and declining wages provide strong 
incentives to leave the labour force” (French, 2005: 396).17 It will be important to 
consider these other factors affecting labor supply when selecting the sample of 
individuals included in this analysis.  Therefore, this analysis focuses on individuals 
ages 55-75, 55-64, and 55-61. 
I estimate specifications on samples split by gender to allow for potentially 
differential responses by sex.  This could be driven by factors such as gender based 
differences in the efficacy of medication or the desire or need to work. I also attempt 
to test for the presence of reverse causality resulting from employer-provided health 
insurance by estimating the labor supply responses of other expensive prescription 
medications intended for chronic conditions.  The specification discussed above 
focuses on the decision to work.  It is also possible, however, that Vioxx affected 
labor supply along the intensive margin.  In particular, individuals taking Vioxx may 
have worked more hours.  Therefore, I will estimate a specification of equation (8) 
using usual hours worked as the dependent variable.   
                                                 
17 For those electing early retirement payments, the labor supply disincentive is increased by the social 
security earnings test. In 2001, for every two dollars in earnings above $10,680, social security 
withholds one dollar.  For earnings above $25,000, one dollar in benefits is withheld for ever three 
dollars in earnings.  This earnings test could result in several of the individuals who were able to enter 
the labor force as a result of Vioxx no longer finding it utility maximizing to continue in the labor 
force and instead choosing to retire.  In estimating the effect of Vioxx on labor force participation it 
will also be important to consider the distortion caused by the normal retirement age (between the ages 
of 65 and 67 depending on an individual’s birth date).  For these individuals there is no longer an 




One concern is that there are person-specific time-varying changes that are 
biasing the estimated coefficients in equation (8).  This fixed effects identification 
strategy is based on the observed decision to start taking Vioxx.  If this decision is 
driven by an unobserved time-varying factor that is correlated with the labor supply 
decision, the estimated coefficients would be biased.  To address this concern, I 
implement an instrumental variables identification strategy that uses the removal of 
Vioxx from the market in late 2004 as an exogenous reduction in the use of Vioxx. 
Due to the fact that the removal of Vioxx was unexpected, differences in the 
utilization of the drug in the post-removal time periods should be uncorrelated with 
any time-varying changes that may be a source of bias in the fixed-effects results. 
 
The Effect of Vioxx on Labor Force Participation 
Table 4 contains the results of the equation (7)—the naïve OLS model.  This 
model finds a statistically significant relationship between taking Vioxx and working 
in the current period for near elderly workers.  The last two rows of estimates are the 
linear combinations of the coefficients for Vioxx use and Vioxx use interacted with a 
dummy variable indicating condition status.  Column (1) contains the effect of Vioxx 
on labor supply for individuals aged 55-61.  For individuals in this group reporting a 
joint condition, Vioxx is associated with a 7.9 percentage point increase in the 
probability of working.  For individuals age 55-64 with a joint condition, the results 
in Column (2) suggest that Vioxx use is associated with a 6.1 percentage point 
increase in the probability of working.  It is likely, however, that these estimates are 




specific characteristics.  There is no statistically significant increase for individuals of 
any age reporting a back condition. 
 Table 5 reports the regression results for the fixed effects model for a number 
of age-based samples.  Focusing on individuals with joint conditions, who were found 
to have a large and statistically significant increase in the probability of working in 
the cross sectional estimates, there is no statistically significant relationship between 
labor supply and Vioxx for any age group. This suggests that the unobserved 
variables generated an upward bias to the naïve estimates of the effect of Vioxx on 
labor supply.  These results cast doubt on any estimates of the economic benefit of 
medical technology that are unable to control for person-level fixed effects.  
To account for potential gender-based differences in the effect of Vioxx, I 
estimated a specification of equation (8) on gender based sub-samples. Table 6 
contains these results for the same age groups as Table 5.  There are statistically 
significant effects on labor supply in the period following Vioxx use for males in all 
three age groups. Column (1) contains the estimates for males between the ages of 
55-61 who report a joint condition. Vioxx use in the current MEPS round is 
associated with a 7.6 percentage point increase in the probability of working for these 
individuals.  This estimate is statistically significant at the 0.05 level.  In the sample, 
approximately 64 percent of men with a joint condition between the ages of 55-61 are 
working.  Therefore, Vioxx use is associated with a nearly 12 percent increase in the 
probability of working for these individuals.  The estimated effects for individuals 




Columns (4) – (6) contain the results for females.  These results are much 
smaller or negative and are not statistically significant at conventional levels. There 
are several possible reasons for this.  First, there could be a differential efficacy of 
NSAID medications based on gender.  In an experimental setting, Walker and 
Carmody (1998) found that men received more analgesic benefit than women from 
the NSAID ibuprofen.  A second possible reason is that women in these age groups 
have a lower level of labor force attachment and overall labor supply.  Finally, the 
lack of an effect could be driven by differences in the physical requirements of 
occupations by sex.  Women are more likely to be employed in jobs that require less 
physical labor and therefore may be less affected by painful chronic conditions. Using 
data from the MEPS on reported occupations, I split the sample based on the amount 
of physical labor required.18  Focusing on the sample of Table 6 which demonstrated 
the strongest results—individuals ages 55-61—only 6.5 percent of women report 
working in a physically difficult occupation during any round in the MEPS.  Under a 
disutility of work framework, it is reasonable to expect that individuals employed in 
jobs requiring more physical exertion would be more likely to receive a benefit from 
Vioxx. 
Table 7 contains results for equation (8) for males in the same age ranges as in 
Table 5.  Due to the relatively small number of individuals that report a back 
condition and a job requiring physical labor, this specification only includes 
                                                 
18 According to the MEPS, current main jobs are coded at the 4 digit level using the Census Industry 
and Occupation coding schemes.  For confidentiality reasons, these codes are condensed into more 
general categories. These condensed categories were changed in 2002. In this analysis, for MEPS 
reference periods before 2002, individuals were classified as having physical jobs if they were the 
following occupations:  craftsmen and foremen; operatives; transport operatives; laborers, not farming; 
farm laborers and foremen; and active military.  After 2002 individuals were classified as having 
physical jobs if they reported being in farming, fishery and forestry; construction, extraction, and 




interaction terms for joint conditions.  Column (1) contains the results for males 
between the ages of 55 and 61 with a joint condition that report a physical occupation 
in at least one period.  In this group there is a statistically significant effect on the 
probability of working for taking Vioxx in the current period of 12.1 percentage 
points and for Vioxx in the previous period it is 13.2 percentage points.  This is nearly 
50 percent larger than the estimates in Table 6.  For males in each age group there are 
statistically significant effects for Vioxx use in the previous period.  Examining males 
with joint conditions age 55-61 who do not report a job primarily requiring physical 
labor, the results in Column (4) show a small but statistically significant increase in 
the probability of working of 3.5 percentage points.  There are no effects for males in 
other age ranges.  Due to the small number of women that report primarily physical 
occupations, these results suggest that the lack of a detectable effect for women may 
be due, at least in part, to differences in the physical nature of their occupations.   
While evidence from clinical trials regarding the relative efficacy of Vioxx 
and Celebrex is mixed, evidence of economic effects may provide some information 
about differential benefits between the two drugs.  Table 8 contains results similar to 
Table 6 with Celebrex as the drug of interest.  There are no positive or statistically 
significant effects for any of the age samples for either sex.  Due to the fact that 
Celebrex was released before Vioxx, it is possible that there are differences in the 
patient mix that are driving these results.  It does not appear, however, that this 
difference in the effect between Vioxx and Celebrex is driven by observable 
differences in the population.  Huse and Marder (2007) examined provided 




individuals were of similar age, sex, region of the country, and insurance status.  This 
similarity in observables suggests that the differences in the patient mix between the 
two drugs are not driving the divergent results.19  
These results suggest that Vioxx provides a greater profile of labor supply 
benefits than Celebrex.  The difference in economic benefits may provide additional 
evidence, beyond those of clinical trials, about the relative pain relieving benefits of 
these two medications.  This may be useful to regulators and other policymakers 
when making decisions about the availability and substitutability of the medications.   
As mentioned above, the linear probability model can produce inaccurate 
estimates when the independent variable is binary.  Therefore, I estimated a 
conditional logit model of the effect of Vioxx on labor supply.  Table 9 contains these 
estimates for the males and females age 55-64 and 55-75.  Due to the restricted 
sample size, smaller age ranges were not estimated.  The results are qualitatively 
similar to the fixed effect results reported above.20  Column (1) contains results for 
males aged 55-64 with a chronic condition.  There is a statistically significant 
increase in the probability of working during the current and subsequent Vioxx 
period.  The odds ratio suggests that odds of these individuals working are more than 
five times greater than individuals who are not taking Vioxx.  There are no 
statistically significant effects for women.   
When interpreting the magnitude of these results it is important to note that 
the smaller sample size in these specifications results from the fact that individuals 
                                                 
19 Similarly, more individuals in the dataset report Celebrex prescriptions than Vioxx prescriptions 
suggesting that a small sample size of Celebrex recipients is not causing the lack of a detectable effect. 
20 Estimating an OLS model on a similarly restricted sample returns qualitatively similar results to 




are only included in the sample if they either enter or leave the labor force during 
their time in the MEPS sample.  This reflects a lower level of labor force attachment.  
For example, the percentage of males between the ages of 55 and 64 in the 
conditional logit sample that are working is 57 percent.  In the full sample, this 
percentage is nearly 75 percent.   
 
Reverse Causality 
One concern related to the results above is a question of the direction of 
causality.  Due to its potentially daily use and lack of generic competition, the yearly 
cost of Vioxx was quite expensive—upwards of $1,000 a year depending on the 
frequency of the dosage and the location.  The primary source of health insurance in 
the United States for those under the age of 65 is an employer.  It is increasingly 
difficult for the near elderly to acquire medical insurance if they are not working—
particularly if they already have a chronic condition such as arthritis.  It could be that 
in order to obtain the insurance necessary to pay for medication individuals enter (or 
remain in) the labor force.  Similar effects have been found in other situations.  
Bradley and Neumark et al. (2005) found suggestive evidence of this effect.  The 
authors found that women with breast cancer whose health insurance was provided by 
their employer had a smaller decrease in labor supply than those whose insurance was 
provided by their spouse’s employer. 
While finding a larger labor supply effect in the period after taking the 
medication limits many of the above concerns, I attempt to confirm the causal 




expensive prescriptions that should not contribute to increased labor supply.  If 
individuals are working in order to pay for medication, a similar response should be 
found for these other expensive drugs.  Unlike Vioxx, I do not present estimates with 
a lagged effect since there is no theoretical reason to suggest such an effect would 
exist.21 After consulting with physicians, I identified a set of prescriptions that are 
both expensive and indicated for chronic conditions and were widely prescribed, but 
are unlikely to improve the ability of patients to participate in the labor force.  These 
drugs include Lipitor for high cholesterol, Nexium for acid reflux, Viagra for erectile 
dysfunction, and Fosamax for osteoporosis prevention.22   For both Lipitor and 
Nexium, the estimated coefficients are interacted with dummy variables indicating 
the presence of high cholesterol and gastroesophageal reflux (acid reflux).  Table 10 
contains results for the males and females in the three age based samples. Each set of 
two rows represents a different specification containing a particular prescription, 
except the last set which estimates the effect for Viagra on males and Fosamax for 
females.  The bottom rows provide the linear combination of the drug and drug-
condition interaction terms.  Unlike Vioxx, the estimated labor supply effects are 
small and statistically insignificant.  Taken together, these results suggest that 
individuals are not working in order to secure their prescription medication and the 
estimated effects of Vioxx above are likely causal. 
 
                                                 
21 These are no statistically significant results for a specification including the lagged effect. 
22 Since Viagra and Fosamax are taken almost exclusively by men and women respectively, the effect 




Effect of Vioxx on Hours Worked 
In addition to allowing people to reenter (or remain in) the labor force, 
pharmaceutical innovations can allow people to increase their work effort.  This 
response along the intensive margin would also generate significant economic 
benefits.  Previous research examining labor supply adjustments along the intensive 
margin finds mixed results. Eissa and Hoynes (2005) examined the response of 
individuals to the EITC.  They found that in general individuals respond along the 
extensive rather than the intensive margin.  The focus of this analysis is a different 
population.  Specifically, the near-elderly nature of the expected beneficiaries of 
Vioxx may lead to a response on the intensive margin.  This is due to the fact that 
near elderly workers are those individuals who are most likely to have the flexibility 
necessary to adjust their hours in response to changes in the ability or desire to work.  
Friedberg (1999) examined the effect of the social security earnings test on labor 
supply of elderly and near elderly workers.  The author found that, “the 
responsiveness of older workers to the earnings test suggests that they enjoy greater 
hours flexibility” (Friedberg, 1999: 50).   
In order to detect the presence of this effect on hours worked in the case of 
Vioxx, I re-estimated a specification of equation (8) with hours worked as the 
dependent variable.  Specifically, the dependent variable is the usual weekly hours 
worked during the reference period, while Vioxx use is defined as any prescription in 
the current or previous period respectively.  Table 11 contains the estimated 
coefficients and standard errors from this specification.  Column (1) contains results 




significant increase in hours worked Vioxx use in the current and previous period.  
This increase in usual weekly hours worked during the reference period following a 
reported Vioxx prescription is 2.79.  The average usual hours worked, among those 
working, for this group is 25.46—suggesting that Vioxx use increases hours worked 
by 10.9 percent. 
   For all age ranges of females with joint conditions there is a statistically 
significant and negative estimate for Vioxx use in the previous period.  This raises 
some concern that changes in factors such as condition severity may be causing a 
downward bias in the causal effect of Vioxx.   
 It is possible that the above results for males are actually a reflection of the 
earlier reported extensive margin results.  For example, the average hours worked for 
55-61 year old males with joint conditions that report positive hours is 42.47.  
Therefore, the 6.9 percentage point increase in the probability of working from Table 
14 should result in an increase in hours worked of approximately 2.93 hours.  This is 
similar to the estimated increase of 2.79 hours in Table 15.   
 In unreported results limiting the sample to respondents reporting positive 
hours there are no statistically significant estimates for any age group. This fact, 
combined with the magnitude of the full sample results being similar to the expected 
results from participation, makes it unlikely that Vioxx caused individuals to adjust 





Instrumental Variables Estimation Strategy 
The fixed effects identification strategy will consistently estimate the impact 
of Vioxx on labor supply under the assumption that there are no time-varying factors 
influencing both Vioxx usage and working.  While this assumption seems reasonable, 
it is possible that there exists an unobserved time-varying factor biasing these fixed 
effects results. In order to overcome the potential endogeneity in the decision to take 
Vioxx, I implement an instrumental variables estimation strategy.  This requires 
identifying a variable that affects the covariate of interest (Vioxx usage) without 
directly affecting the individuals’ labor supply.  I will use the removal of Vioxx from 
the market in September 2004 as an exogenous change in the drug’s utilization.23  
Guided by both disability rates and my previous results, I focus this analysis on the 
labor supply response of individuals most likely affected by the removal of Vioxx—
those reporting chronic joint conditions.  Specifically, I will instrument for a decrease 
in Vioxx usage with a dummy variable indicating the time period where Vioxx is 
removed interacted with a dummy variable equal to 1 if the individual reports a 
chronic joint condition in any MEPS round.  It is a reasonable assumption that the 
decision to remove Vioxx from the market did not directly affect the labor supply 
                                                 
23 I also attempted a similar strategy using the “black box” warning label placed on Vioxx in April, 
2002.  This warning label reflected the newly discovered increased cardiac risk.  The warning label did 
appear to lower usage of Vioxx reflected by both the downward trend in Figure 2 and a negative and 
statistically significant coefficient on Vioxx in a specification of equation (8) estimated using data 
from MEPS Panel 7.  There is no corresponding decrease in labor supply.  This could be evidence of 
individuals who stopped taking Vioxx following the warning being individuals who did not require the 
medication to work.  A common criticism of Vioxx was that it was over prescribed, potentially as a 
result of a large amount of direct-to-consumer advertising (Dai et al., 2005).  The lack of an effect on 
labor supply from this earlier warning demonstrates the requirement of a complete removal of the drug 
from the market as an exogenous source of variation in utilization.  Without a complete removal there 




decision of individuals with chronic joint conditions through a channel other than the 
absence of the medication. 
Successfully implementing this identification strategy requires data on the 
labor supply and prescription drug use of individuals before and after Vioxx is 
removed from the market.  The 9th panel of the MEPS dataset contains individuals 
interviewed during 2004 and 2005.  This is the only panel overlapping the removal 
decision.24  The relatively small sample size of a single panel requires me to use the 
largest age-based sub-samples from the fixed-effects analysis—respondents between 
the ages of 55 and 75.  
The underlying hypothesis of this study is that the use of Vioxx decreases the 
pain from chronic conditions allowing individuals to increase their labor supply.  If 
this were the case, the removal of Vioxx should increase the reported health problems 
among previous Vioxx users.  Figure 5 contains the reported activity limitation status 
for individuals with joint conditions based on their Vioxx use before and after the 
medication was removed from the market.  In the time period after removal, there was 
a 19 percent increase in the percentage of individuals with joint conditions that were 
previously taking Vioxx who report an activity limitation.  There was essentially no 
change for other individuals with joint conditions.   
The structural equation of interest is equation (8).  The concern is that this 
equation cannot be consistently estimated with OLS because the error term may be 
correlated with the use of Vioxx.  Specifically, the concern is that the structure of the 
                                                 
24 This panel of the MEPS is the only group that includes observations for individuals in the time 
period both before and after the removal of Vioxx from the market.  Another conceivable event for an 
IV strategy is the introduction of Vioxx in 1999.  Unfortunately, Vioxx slowly penetrated the market 





error term is, ititit ρσε += , where the cov(VIOXXit, itσ ) ≠ 0 and therefore the 
estimated causal effect of Vioxx on labor supply would be biased.  As was discussed 
above, one possible factor causing a downward bias would be changes in condition 
severity driving both the use of Vioxx and a decrease in labor supply.  More 
concerning are omitted variables that may be positively correlated with both working 
and Vioxx and therefore would generate an upward bias in the causal estimates of 
labor supply.  One such factor could be changes in the desire or need to work.  
A key criterion of an effective instrument is that it directly affects the 
covariate of interest.  Figure 6 contains the percentage of individuals reporting a 
Vioxx prescription during 2004 and 2005.  As would be expected, the removal 
dramatically decreased the percentage of the population reporting a Vioxx 
prescription.  The percentage of people receiving Celebrex and Lipitor are also 
included in the chart.  Celebrex shows a slight decline that is likely a result of 
negative publicity from the Vioxx recall.  Lipitor prescriptions increase throughout 
the removal time period—suggesting that the decrease in Vioxx prescriptions is not 
the result of a secular time trend in prescription usage. The sharp decline makes it 
unlikely that time-varying factors other than Merck’s decision were the cause of this 
drop in utilization.  More formally, it is required that the estimated coefficient on the 
instrument from a linear projection of the endogenous covariate of interest onto all 
exogenous variables must be non-zero.  This linear projection is described as the 
“first stage” relationship and in this case takes the following form:  
 





Where VIOXXit is a binary variable equal to 1 if person i reports a Vioxx prescription 
during reference round, tυ  is a dummy variable for the MEPS round, and 
REMOVEt*JOINTi is the interaction between being in the time period where Vioxx 
is not being sold and a binary variable equal to one if an individual reports the 
presence of a joint condition during any MEPS round.25  The coefficient of interest 
is 1β  which represents the effect on utilization from Vioxx being removed from the 
market for individuals with joint conditions.   
One possible reaction to Vioxx’s removal is that patients and physicians 
would simply switch their prescriptions to other COX-2 inhibitors.  Data from both 
the MEPS and other sources suggests that this does not appear to have been the 
reaction.  Instead, it appears that the removal of Vioxx created a “class effect” that 
limited the willingness of doctors to prescribe or patients to utilize all NSAIDs.  This 
effect could result from Vioxx users receiving little analgesic benefit from other drugs 
or a general uncertainty regarding the safety profile of the entire class of drugs.  This 
class effect was exacerbated by the removal from the market of Bextra, an alternate 
COX-2 inhibitor, in early 2005.  
If changes in the utilization of all COX-2 inhibitors were caused by changes in 
a physician’s willingness to prescribe the medications, the reduced utilization of these 
other drugs after Vioxx’s removal can be reasonably interpreted as a further 
exogenous change and should be included in the first-stage estimation.  Therefore, I 
                                                 
25 In this case, the Vioxx is considered “removed” from the market during the 3rd, 4th, and 5th rounds of 
Panel 9 of the MEPS.  The removal occurs during the beginning of the 3rd round.  The reference period 
for over one quarter of the respondents did not begin until after the drug was removed, and nearly all of 




will also estimate a specification of equation (8) with all COX-2 inhibitors as the 
dependent variable.  Failing to consider this class effect and estimating a first-stage 
relationship with only Vioxx as the dependent variable will underestimate the first-
stage coefficient. Since in an exactly identified model the IV coefficient is the ratio of 
the reduced form coefficient to the first stage coefficient, underestimating the first 
stage relationship will, by construction, generate an upward bias in the IV estimates. 
This bias exists if the inability of individuals to access these medications is causally 
related their labor supply.   
The potential bias can also be thought of as the use of other COX-2 inhibitors 
being an omitted independent variable in the structural equation. Failing to account 
for the relationship between the instrument and this omitted variable will bias in the 
IV estimate.  Estimating a first-stage equation with a dependent variable accounting 
for all COX-2 inhibitors eliminates this bias. 
 The reduced form relationship estimates the effect of the removal of Vioxx on 
labor supply.  Figure 7 contains the labor supply of individuals with joint conditions 
based on their Vioxx status. This figure provides suggestive evidence of the reduced 
form relationship.  The labor supply of individuals with joint conditions who had ever 
taken Vioxx moved down in the periods where Vioxx was no longer available, while 
the labor supply of individuals with chronic joint conditions but no reported Vioxx 
use remains virtually unchanged. The reduced form equation is: 
 





Where WORKINGit is a binary variable equal to 1 if respondent i reports working in 
time period t, and all other variables are defined as in equation (8).  The coefficient of 
interest is again 1β , which represents the probability of working in the post-Vioxx 
time periods for individuals reporting a joint condition in at least one MEPS round.  
 Table 12 contains the results of a specification of equation (8) estimated on 
the 9th panel of the MEPS.  Due to sample size concerns, these results focus on the 
largest age group used in the fixed effects results—individuals aged 55-75.  In 
addition, the results are presented for individuals with joint conditions—those most 
affected in the fixed-effect results.  Vioxx use in the previous period is associated 
with a 4.4 percent increase in the probability of individuals with joint conditions 
working. This is similar in magnitude to the estimated effect in Table 6. 
Table 13 contains the IV results using the September 2004 removal of Vioxx 
from the global market as an instrument for changes in the usage of Vioxx.  Column 
(2) reports the first stage results for a sample of individuals between the ages of 55 
and 75.  As would be expected, the removal of Vioxx from the market caused a 
statistically and economically significant decrease in the usage of the medication by 
individuals suffering from chronic joint conditions.  Specifically, removing Vioxx 
from the market reduced the probability an individual a chronic joint condition filling 
a Vioxx prescription by 5.8 percentage points.  The F-test statistic that the coefficient 
on the instrument is zero is 48.62, suggesting that finite sample bias is not a concern 
in this case.  Overall, the magnitude and direction of these results are not surprising.  
Roughly 7 percent of individuals with joint conditions filled a Vioxx prescription in 




Column (2) of Table 14 contains first stage estimates for the effect of Vioxx’s 
removal on the use of the most widely prescribed COX-2 inhibitors—Vioxx, 
Celebrex, and Bextra.  This removal resulted in a reduction of 10.2 percentage points 
in COX-2 usage.  This larger result is not surprising since a higher proportion of 
arthritics were using all COX-2 inhibitors than those using only Vioxx.   
 In Column (1) of Tables 13 and 14, I report results for the reduced form 
equation (10) for all individuals between 55 and 75.  The coefficient on the 
instrument suggests the probability of working for those with a chronic joint 
condition is 2.4 percentage points lower in the post-removal MEPS rounds.   
 In the case of an exactly identified model, the IV coefficient is the ratio of the 
reduced form to the first stage regression.  Column (3) of Table 13 contains the IV 
results for the model containing only Vioxx. These results suggest that Vioxx 
increases the probability of working for individuals with chronic joint conditions by 
41 percentage points.  During the second round of panel 9, only 41.6 percent of 
individuals with chronic joint conditions between 55 and 75 were working.  If the 
magnitude of these IV results is to be believed, they suggest that nearly all of these 
individuals left the labor force as a result of Vioxx leaving the market.  The size of 
this coefficient is concerning, suggesting that solely focusing on Vioxx may have 
generated an upward bias in the IV estimates.   
Column (3) of Table 14 contains the IV results for an exactly identified model 
where the first stage is defined as the effect of Vioxx’s removal from the market on 
all COX-2 inhibitors.  The coefficient here suggests a more reasonable 23.7 




smaller than the IV results using only Vioxx prescriptions in the first stage, this 
estimate is still larger in magnitude than the fixed effects results presented earlier.  
There are several reasons why this may be the case.  First, this estimate represents the 
local average treatment effect (LATE) for individuals who want to take a COX-2 
inhibitor but are deprived of the opportunity by the removal decision.  This is a 
different sample than the individuals in the fixed-effects sample who are choosing to 
take the medication.  This is particularly true given the fact that concerns of the safety 
of Vioxx caused use of the drug to decline from 2002-2004, suggesting that the 
remaining users may have a particularly strong preference or need for the medication.  
For this reason it is perhaps not unexpected that the LATE is greater than the 
estimated effect from the fixed effects analysis.   
It is also possible that the vast amount of news coverage affected the use of 
analgesic medications beyond COX-2 inhibitors.  In particular, users of other 
NSAIDs may have been deterred from using their medications or doctors may have 
given stronger warnings to patients regarding the use of both prescription and over-
the-counter painkillers. Finally, the higher IV results could also be evidence of a 
downward bias in the fixed effects results caused by increases in condition severity 
driving Vioxx use.  
 It could be that the change in the probability of working for individuals with 
joint conditions following the removal of Vioxx is actually related to a more general 
change in the ability or willingness of those with chronic conditions to work.  If this 
were the case, then similar results to those in Tables 13 and 14 should appear for 




above for individuals suffering from chronic conditions that should not have been 
directly affected by the removal of Vioxx.  Specifically, I estimated the model for 
individuals with heart conditions,26 and respiratory conditions.27  These conditions are 
associated with increased rates of short-term disability insurance and SSDI receipt 
(Wagner et al., 2000). 
 Tables 15 and 16 contain the results for these models. There are no 
statistically significant results for any of the IV estimates.  Neither group exhibits a 
negative labor supply response during the post-Vioxx period.  These results suggest 
that the IV estimates for arthritic labor supply are not being driven by secular changes 
in the ability of individuals with chronic conditions to work.  
 
Conclusion 
  Taken together, the above results suggest that Vioxx had an economically and 
statistically significant impact on the labor supply of near elderly men.  An 
approximate calculation using my IV results may provide some insight into the 
magnitude of the effect of COX-2 inhibitors on near elderly labor supply.  In the 
MEPS sample, approximately one third of males between the ages of 55 and 65 with 
a joint condition are not working.  If the rate of use of COX-2 inhibitors is the same 
among this group as all individuals with joint conditions in the MEPS sample, 
approximately 30 percent, and these drugs have the estimated effect on labor supply 
from the IV results, these drugs would have increased the overall near-elderly male 
labor force participation by 0.58 percentage points.  Considering that between 1996 
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and 2005 labor force participation this group increased by 2.5 percentage points, this 
approximate net effect of COX-2 inhibitors on near-elderly labor supply is 
economically significant.   
Vioxx is only one example of a medical innovation that may have 
demonstrable economic impacts.  Other innovations such as improved treatments for 
heart attack victims, joint replacements, and new prescription medications addressing 
a wide variety of chronic conditions, may also improve the economic livelihood of 
individuals.  The Conference Board estimated that from 2005-2010, the number of 
55-64 years old in the labor force will increase by 52 percent (Foster and Sedlar, 
2005).  This estimate does not take into account potential changes in labor supply 
resulting from increases in medical technology.  Due to the fact that a large number of 
chronic conditions are more likely to strike older individuals, this increase in the 
working age population could lead to more individuals requiring medical assistance 
to participate in the labor force.  Further research is needed to determine the impact of 
other medical innovations on economic outcomes such as labor supply.  This study 
demonstrates that exogenous changes in utilization of medical technology may serve 
as effective methodology for identifying the economic effects of other innovations.  
Such changes in utilization could be caused by price shocks due to drugs losing patent 
protection, changes in co-payment structure, or discount drug programs. 
   The ability of individuals with chronic conditions to reenter or remain in the 
labor force can have important societal benefits.  For example, many of these 
individuals currently receive either private or government disability payments. 




(Bhattacharya and Schoenbaum, 2002).  Examining MEPS respondents by age and 
arthropathy status shows that in each age group the percentage of individuals 
reporting positive SSI incomes is greater for individuals with a chronic joint 
condition.  Autor and Duggan (2003) stated that between 1984 and 2001 there was a 
60 percent increase in the number of adults receiving Social Security Disability 
Insurance (SSDI). As the labor force continues to age, this trend towards increased 
disability enrollment will likely continue. To the extent that advancements in medical 
technology can affect the number of individuals who are working rather than 
receiving disability payments, these technological improvements can represent a net 
societal benefit.    
In addition to the effects on social disability programs, explicitly accounting 
for the economic benefits of new medications can have far reaching impacts on the 
regulation of pharmaceuticals.  Under the 1962 Kefauver-Harris amendments, 
pharmaceutical companies must demonstrate to the Food and Drug Administration 
(FDA) that new innovations are both safe and effective in order bring drugs to 
market.  To do so, firms present evidence from random assignment clinical trials, 
which traditionally have focused on objective medical outcomes. For example, in 
evaluating cancer medications, both mortality and tumor size are used as measures of 
drug’s efficacy.  Drugs whose benefits can be measured solely in objective medical 
terms are becoming less common.  Increasingly regulators rely on patient reported 
outcomes (PROs) to judge efficacy. From 1997-2002, thirty percent of FDA approved 




These included reduced pain, depression status, and changes in energy levels that are 
often associated with quality of life medications (Bren, 2006). 
In making the approval decision for a drug such as Vioxx, regulators must 
determine the appropriate degree of safety risk that is acceptable to achieve quality of 
life improvements.  Answering this question should require the FDA to account for 
the full scope of benefits provided by the drug—including both medical and 
economic outcomes.  Properly accounting for PROs, however, is a continuing 
difficulty for the FDA. This fact led the National Institute of Health (NIH) to create a 
commission tasked with developing a more effective means of quantifying and 
evaluating these outcomes.  Former NIH Director Elias A. Zerhouni said “there is a 
pressing need to better quantify clinically important symptoms and outcomes that are 
now difficult to measure” (Bren, 2006).  The current inability to fully quantify PROs 
suggests a need for additional metrics for evaluating the efficacy of quality of life 
medications.  This analysis suggests that economic outcomes may be a useful metric 
in fully defining the benefit profile of quality of life medications.  
Previous authors have evaluated the net health benefits of advancements in 
medical and pharmaceutical technology, but have generally not included economic 
effects in their benefits profile.  Cutler and McClellan (2001) and Skinner et al. 
(2006) found that, on net, technology-driven cost increases were smaller than their 
benefits. Lichtenberg (2001) found that individuals consuming newer drugs had lower 
mortality and lower non-drug medical spending. In contrast, Duggan (2005) analyzed 
the cost-effectiveness of second generation anti-psychotics and found that the drugs 




effects on non-medical outcomes such as labor supply or wages.  Excluding economic 
outcomes is particularly damaging for quality-of-life pharmaceuticals, which may be 





Chapter 2: The Effect of In-Utero Conditions on Long Term Health: 
Evidence from the 1918 Spanish Flu Pandemic 
 
The differing incidence of chronic health conditions by individuals with 
similar backgrounds, lifestyles, and blood chemistry has caused medical professionals 
and health economists to look beyond these factors for other sources of later life 
health problems.  Spurred by a compelling correlation between birth weight and 
elderly health, this search has increasingly focused on fetal conditions.  This literature 
is often referred to as the “fetal origins hypothesis” or the “Barker hypothesis.” 
According to these theories, in-utero malnutrition or other factors decreasing fetal 
health cause a shift of blood and nutrients from vital organs to the brain.28  This 
diversion is an attempt to protect the fetus and improve the chances for immediate 
post-natal survival, but leaves certain organs preprogrammed for failure in later life—
often after 50 years or more.   
 Controlled experiments using animal subjects provide the most complete 
evidence to date of the fetal origins hypothesis.29   The evidence for humans is 
decidedly less conclusive.  The bulk of studies at this point are primarily cross-
sectional in nature with most showing adults born with low birth weights having 
higher rates of particular diseases and mortality.  These studies, however, suffer from 
the problem that low birth weights might signal other unmeasured characteristics that 
predict higher adult mortality.  Absent random assignment, the best hope for testing 
the fetal origins hypothesis is through quasi-experimental variation in fetal 
                                                 
28 For an excellent discussion of the fetal origins hypothesis, see Barker (2001) 




conditions.  For example, economists have separately used famines and the 1918 flu 
pandemic as an exogenous source of fetal stress.  Previous research using famines, 
however, has found only mixed evidence in support of the fetal origins hypothesis.  
As shown in Almond and Mazmunder (2005), and discussed in detail below, the short 
term and intense nature of the 1918 flu pandemic creates a better design for 
estimating the long term health impacts of fetal stress.   
Often called the Spanish flu, the 1918 global flu pandemic killed between 50 
and 100 million people in the course of a single year.  In the United States, it struck 
hardest during the last quarter of 1918.  Its effects largely dissipated by the first 
months of 1919.  Over this time period, the flu killed 675,000 people—more than 
AIDS has ever killed in the United States (Barry, 2004).  Despite its virulence, 25 
million Americans contracted the flu and survived.   
Women of childbearing age and pregnant women suffered some of the worst 
effects from the pandemic with approximately one third becoming infected (Almond, 
2006).  Mortality among pregnant women during this time period was similarly 
increased (Rasmussen et al., 2008).  Barry (2004) stated, “in thirteen studies of 
hospitalized pregnant women during the 1918 pandemic, the death rate ranged from 
23 percent to 71 percent” (p. 241). While the death rate was high for pregnant 
women, many survived and carried the child to term.  Among women that survived, 
fetal health appears to have been negatively impacted.  Almond (2006) reported that 
stillbirth rates increased by approximately 40 percent during the October-December 
1918 period.  This decrease in fetal health was also found in other pandemics and in 




exposure to influenza results in a higher rate of complications in pregnancy and 
decreased fetal health.  
The disproportionate impact of the flu on pregnant women, the corresponding 
decrease in fetal conditions and health, and the relatively random nature of the 
outbreak provides a clear design for testing the fetal origins hypothesis using the 1918 
pandemic.  While the source of stress caused by being in-utero during the peak of the 
1918 flu pandemic is different from famines or other sources of nutrient deprivation, 
is it clear that this exposure worsened in-utero conditions and greatly decreased fetal 
health.  The long term effects of this decreased fetal health can provide important 
insights concerning the programming effects of in-utero conditions.  
Almond (2006) exploited this fact to examine differences in education levels 
and disability rates for individuals exposed to the flu pandemic in-utero.  Almond and 
Mazmunder (2005) examined specific medical conditions using roughly 25,000 
observations of adults in the 1915 to 1923 birth cohorts from the Survey of Income 
Program Participation (SIPP).  The authors find evidence of an impact from in-utero 
flu exposure on a variety of health outcomes such as stroke, diabetes incidence, self 
reported health status, and trouble hearing, talking, walking, and lifting.   
This study uses the larger National Health Interview Survey (NHIS) dataset to 
expand upon these earlier results.  Specifically, I use 21 years of repeated cross-
sections of the NHIS to examine the impact of the 1918 flu pandemic on the 
incidence of coronary heart disease, diabetes, kidney disorders, and poor health 
status.  The sample used in this work contains approximately 384,000 observations or 




An advance of this work over previous efforts is an attempt to test precise 
predictions from animal studies and the medical literature about when exposure to in-
utero insults should damage organs later in life.  Nathanielsz (2006) stated “critical 
time windows exist during development when organs are vulnerable to challenges 
such as decreased oxygenation, nutrient supply, and altered hormone exposure.  The 
period of vulnerability varies from organ to organ” (p. 74).  Medical knowledge of the 
progress of fetal organ development leads to relatively precise predictions of the 
effect of differential timing in fetal insults.  As will be discussed in more detail 
below, the heart primarily develops early in gestation and thus individuals who are 
affected by the flu in the early-to-middle months of pregnancy are hypothesized to be 
a higher probability of heart disease later in life.  Similarly, the nutrition delivery 
system is developed early in pregnancy suggesting that individuals affected during 
the first months of pregnancy are thought to be more likely to develop metabolic 
disorders later in life.  At the other extreme, the kidneys primarily develop during the 
last months of pregnancy.  Individuals affected during these last months may be more 
likely to develop kidney disorders later in life.  Overall, this study finds statistically 
and qualitatively significant increases in chronic conditions during the time periods 
predicted by the medical literature.  
This time connection provides quasi-experimental evidence of the mechanism 
underlying the fetal origins hypothesis in humans and confirms that the timing of fetal 
stress is critically important in predicting which organs are weakened.  Furthermore, 
these strong and consistent results show that an identification strategy involving the 




particular months of development. As a result, the estimates in the analysis stand in 
contrast to the previously mixed results from other identification strategies.    
Medical Basis of the Fetal Origins Hypothesis 
The most complete evidence to date supporting the fetal origins hypothesis 
comes from experiments with animals where researchers alter uterine conditions by 
either depriving the mother of nutrients or stopping nutritional transfer to the fetus 
through uterine blood flow restriction (Ozanne et al., 1996; Blondeau et al., 1999; 
Simmons et al., 2001).  These restrictions have been imposed both throughout the 
entire gestation and during particular periods of in-utero development.  They have 
also been paired with differing post-natal nutrition levels in order to determine if a 
discrepancy between conditions in these time periods is important (Ozanne and Hales, 
1996). In total, these studies have shown that periods of fetal stress in rats, sheep, and 
other animals cause a weakening of the vital organs that manifests itself in poor later 
life health.    
Among humans, in the medical literature, poor in-utero conditions have been 
linked to a variety of ailments.  These studies, however, rarely utilize exogenous 
variation in fetal conditions creating a concern of an omitted variable bias. Three of 
the more frequently cited outcomes in the medical literature link fetal conditions to 
coronary heart disease, diabetes, and kidney disorders (Barker, 2001).  These are the 
conditions focused on in this analysis. 
 Barker (1992) first noted the striking relationship between low birth weights 
and heart disease rates using a unique data set of births from Hertfordshire, England.  




Helsinki.  Similar findings have been documented in North America, India, and 
Europe (Leon et. al, 1998; Frankel et al., 1996; Rich-Edwards et al., 1997; and 
Eriksson, 2001).  The biological mechanism thought to be the source of this link is 
the diversion of blood and nutrients to the brain and away from other vital organs.  
This represents an evolutionary response designed to protect the brain and increase 
the likelihood that the fetus will survive until and immediately after birth.  This 
process is also an attempt to condition the fetus for a lifetime of deprivation.  
Evidence of this phenomenon has been documented in animal experiments (Barker 
and Hanson, 2004).  For example, the development of the heart muscle is believed to 
be affected by fetal stress.  Unlike other organs, the heart does not begin as a 
miniature version of its fully developed shape.  Instead, it grows throughout the first 
half of pregnancy from a mass of cells into its final complex form (Thornburg, 2001).  
As a result, complications or insufficient nutrition during the early-to-mid period of 
embryonic development is critical for future heart health.  Hoet and Hanson (2001) 
stated, “it appears that the timing of the insult in gestation is all-important, with 
insults occurring earlier having greater effects on cardiovascular development in the 
offspring” (p. 78).  Medical theory predicts an increased incidence of coronary heart 
disease concentrated among, but not limited to, individuals born in the first and 
second quarters of 1919.  These individuals were exposed to the pandemic during 
their first and second trimesters—the critical time period in terms of fetal 
development for future cardiac health. 
 A second group of conditions believed to arise from poor in-utero nutrition are 




mellitus (NIDDM) or Type II diabetes.  Hales et al. (1997) states, “archival records of 
early life anthropometry have shown that reduced birth weight, weight at 1 year, and 
thinness at birth are strongly associated with an increased susceptibility to NIDDM 
and IGT (impaired glucose tolerance) in adult life and to insulin resistance” (p. 191).  
Hales et al. (1991) found that men who have the lowest birth weights were seven 
times more likely to have diabetes and/or insulin resistance than those who were 
heaviest at birth.  Often described as the “thrifty phenotype hypothesis,” this process 
is believed to be an attempt to condition the fetus for future periods of poor nutrition.  
Upon receiving adequate nutrition later in life, the individual is thought to be more 
likely to develop metabolic disorders (Hales and Barker, 1992).  The importance of 
the difference between in-utero and after birth nutrition is illustrated by the relative 
lack of metabolic disorders in African countries—where poor nutrition in-utero is 
followed by equally poor infant and lifetime conditions (Stocker, et al., 2005).30  This 
observation has also been supported by animal experiments where rats who were 
deprived of nutrients in-utero and then given generous diets after birth suffered worse 
health outcomes than similar rats who had a restricted calorie diet during life, though 
both had poor health outcomes overall (Ozanne and Hales, 1999, 2004).   
   Studies examining the effect of under nutrition on later life metabolic 
disorders have found that it is specifically early exposure to poor nutrition that 
fundamentally changes the nutrition delivery system of the fetus (Harding and 
Gluckman, 2001).  Based on this fact, individuals born during the second quarter of 
                                                 
30 The importance between this difference in nutrition and not solely in-utero nutrition could have 
important implications for optimal program design.  Focusing government nutrition programs on the 
post-natal time period without adequate in-utero nutrition could, perversely, increase long term health 




1919, and therefore exposed to the peak of the flu pandemic early in gestation, are 
hypothesized to have a higher probability of reporting the presence of diabetes.   
 In-utero malnutrition and other complications are also believed to decrease the 
size and, as a result, the later life functioning of kidneys.  Restricted diet animal 
studies have shown reduced neonatal kidney weights.  This small kidney size is 
believed to be irreversible by adequate post-natal nutrition (Thornburg, 2001).  In 
humans, cross-sectional analysis has demonstrated a correlation between the number 
of nephrons (the basic structural units of the kidney) and birth weight.  Brenner and 
Mackenzie (1997) state “low birth weight in humans resulting from intrauterine 
growth retardation may be associated with deficits in nephron numbers of up to 20%, 
even in full-term pregnancies” (p. 124).  In turn, low nephron numbers are associated 
with renal disease later in life (Brenner and Chertow, 1993,1994).  Without 
measuring the number of nephrons, Lackland et al. (2001) found a correlation 
between end stage renal disease (ESRD) and low-birthweight.  Similarly, Martyn et 
al. (1996) found connections between later life renal functions and fetal growth.   
 Knowledge of fetal development provides predictions regarding the timing of 
fetal stress and later life renal disease.  The kidneys experience dramatic growth 
during the last months of pregnancy (Martyn and Greenwald, 2001). Studies show 
that “60% of the normal complement of nephrons are laid down during the last 
trimester” (Lackland et al., 2001: 66).  Therefore, the imposition of fetal stress during 
the last months of pregnancy is thought to result in kidney disorders in later life.  This 
would suggest a higher probability of kidney problems in later life for individuals 




Exogenous Variation in Fetal Conditions 
Efforts to document the fetal origins hypothesis in humans are plagued by an 
inability to separate the cause of fetal stress from other factors that generate poor 
long-term health outcomes.  This presence of omitted variables bias casts doubt on 
the accuracy of many previous estimates.  Even when a source of exogenous variation 
in fetal conditions can be identified, the lack of high quality data on both fetal 
conditions and long-term health outcomes is often a substantial problem.  This lack of 
data limits many estimates to outcomes at relatively young ages.  For example, 
Banerjee et al. (2007) examined the long term health effects of the phylloxera 
outbreak in France on long-term health outcomes.  This outbreak destroyed wine 
crops throughout the countryside depressing economic conditions for many families.  
The authors are able to show that men born in wine producing regions were shorter 
upon entrance into the army twenty years later.  Due to the lack of long-term health 
data, however, the authors are unable to test the hypothesis that certain organs (such 
as the heart or metabolic system) are preprogrammed for failure in later life. 
 One frequently utilized source of exogenous variation in fetal conditions is 
famines.  Authors have used the Dutch famine during World War II (Roseboom et al., 
2000; Roseboom et al., 2001; Ravelli et al., 1997), the Chinese Famine (Meng and 
Qian, 2006), the Siege of Leningrad (Stanner and Yudkin, 2001), and the American 
Dust Bowl (Cutler et al., 2007) to investigate the long run health effects of fetal 
stress.  The results of these studies have provided mixed evidence regarding the 
importance of fetal origins.  Roseboom et al. (2000) found differences in heart health 




born during the Dutch famine.  This effect was more pronounced for individuals who 
later became obese.  Meng and Qian (2006) found that individuals born during the 
Chinese famine were shorter in later life, but found no evidence of increased coronary 
heart disease or other traditional outcomes of the fetal origins hypothesis.  Similarly, 
Stanner and Yudkin (2001) found no connection between later life metabolic health 
and poor fetal conditions for individuals born during the Siege of Leningrad.  Cutler 
et al. (2007) found no connection between income shocks resulting from the living in 
the Dust Bowl in the Great Depression and later life mortality, chronic condition 
status, or disability rates.  
 Almond (2006) was the first study in the economics literature to use in-utero 
stress caused by the 1918 Spanish flu pandemic as a source of exogenous variation in 
fetal conditions.  As was discussed above, biological differences in the virulence of 
the pandemic flu make it particularly well suited as a source of variation.  Standard 
influenza strains affect primarily the young, the old, and those with compromised 
immune systems.  This effect can be seen by the “U” shaped dotted line in Figure 8 
representing female deaths during the 1917 flu season.  The 1918 flu, however, 
affected individuals in a decidedly different manner.  Barry (2004) stated, “in 1918, 
the immune system of young adults mounted massive responses to the virus.  That 
immune response filled the lungs with fluid and debris, making it impossible for the 
exchange of oxygen to take place.  The immune response killed [the young and 
healthy]” (p. 250). This excessive immune response caused many of the deaths from 
the 1918 flu to occur among young and relatively healthy individuals.  This effect can 




demographics of those most affected by the flu was particularly true for pregnant 
women who suffered greatly during the pandemic.  Among surviving women, 
evidence of higher rates of miscarriages and stillbirths suggests that overall fetal 
health was greatly decreased. 
 As discussed above there are two main papers in the economics literature that 
investigate the long term consequences of the pandemic flu.31  Almond (2006) used 
this variation to examine the effect of fetal stress on economic outcomes such as 
educational attainment, wages, and disability rates.   In a second study, Almond and 
Mazmunder (2005) used ten panels of the SIPP from 1984-1996. In total, their sample 
included approximately 25,000 individuals born between 1915 and 1923.  The 
authors estimated a linear probability model to determine the affect of being in-utero 
during the peak of the flu pandemic on a variety of health outcomes.  They found 
statistically significant effects at the quarter of birth level for trouble hearing, trouble 
speaking, trouble lifting, trouble walking, diabetes, and stroke.  A larger group of 
health conditions including heart conditions and kidney problems are significant in at 
least one month of birth.  These results were significant at that 0.10 level.  This 
analysis expands upon their work using a dataset with a larger sample size.  This 
larger dataset allows for more precise estimation of the effect of the flu and explicitly 
connects the development of chronic conditions to particular time periods of fetal 
stress.  This connection aids in the understanding of the dynamics of the fetal origins 
hypothesis. 
                                                 
31 Other studies outside of the economics literature have focused on the effect of exposure to the flu 
early in life, but post-natal, on later life health outcomes.  For example, Azambuja (2004) estimated a 




 An advantage of the flu pandemic over famines as an exogenous source of 
fetal stress is the short-term yet intense nature of the outbreak.  As can be seen in 
Figure 9, 1918 represented a sixteen fold increase in flu deaths. This is followed by a 
dramatic decline in the following year. This is a shorter and more intense “treatment” 
period than the Chinese famine or the Siege of Leningrad, which carried on for 
several years.  Babies born during these longer events experienced both poor in-utero 
conditions and nutritional deprivation during infancy.  Disentangling these effects is 
difficult and limits the ability of famines to stand as a test of the fetal origins 
hypothesis as opposed to a test of the long term effects of child health conditions.  In 
contrast, the more discrete nature of the pandemic flu improves the chance of 
isolating the long term impacts of this event from secular changes occurring at the 
same time. 
Data 
The data for this analysis comes from the 1982-2002 NHIS, the principal 
source of health statistics and information for the non-institutionalized population in 
the United States.  While the survey has been in existence since 1957, information on 
the month and year of birth of respondents has only been collected since 1982.32  
During the time period in this sample, the NHIS was substantially redesigned.  In 
both designs of the survey (before and after 1996) individuals were asked about their 
health in regards to coronary heart disease, poor health, diabetes, and kidney 
                                                 
32 The lack of data prior to 1982 limits this analysis because individuals affected by the flu epidemic 
have already turned 62.  This could make it difficult to detect an effect from the flu because many of 
those individuals affected could have already passed away by this age.  This issue of mortality for 




disorders.33  Data for kidney disorders, however, are not comparable across the two 
survey designs and therefore only respondents from 1982-1996 are used with respect 
to kidney disorders. An advantage of the NHIS is that it contains detailed questions 
about disease prevalence.  A disadvantage, however, is that all health data are self-
reported leaving open the possibility of measurement error.   
After pooling cross sections of the NHIS from 1982 to 2002, the observations 
are grouped into quarter of birth cohorts.  Individuals born during the last quarter of 
1918 and the first two quarters of 1919 were affected by the flu in-utero.  Based on 
this fact, individuals in this dataset affected by the flu are between 62 and 84 years of 
age.  The overall sample for this analysis is limited to individuals of similar ages to 
the cohort affected by the flu.  Respondents younger than 55 or older than 90 years of 
age are eliminated from the sample, resulting in approximately 384,000 observations 
ranging in year of birth from 1891 to 1947.  Table 17 provides descriptive statistics 
for this sample compared to similarly aged individuals in the 1980-2000 United States 
Census five percent micro samples.  In total, individuals in the NHIS are more likely 
to be female, Black, Hispanic, and a high school graduate.   They are slightly less 
likely to be a married. 
 
                                                 
33 Prior to 1996 individuals are asked to identify the presence of chronic conditions.  For the purposes 
of this analysis, individual identifying themselves with ischemic heart disease, hearth rhythm 
disorders, congenital heart disease, or other diseases of the heart (excluding hypertension) are 
classified as having coronary heart disease.  Following 1996, individuals are asked individual 
questions about chronic conditions and those saying they have coronary heart disease are classified as 
such.  Individuals are asked in both survey designs about the presence of diabetes.  Prior to 1996, 
individuals are classified as having kidney disorders if they report have kidney infections or “other 





Many individuals born during the last quarter of 1918 and the first two 
quarters of 1919 experienced higher levels of fetal stress (Barry, 2004).  If the fetal 
origins hypothesis is correct, these individuals should have increased rates of chronic 
health conditions in later life compared to individuals born in surrounding time 
periods.   
While the identification strategy in this analysis is similar to that used in 
Almond (2006), there are several differences in the NHIS data that necessitate 
altering his basic specification.  All dependent variables are defined as the presence of 
chronic conditions and are thus binary.  In the presence of a binary dependent 
variable, the linear probability model can produce inaccurate estimates, especially 
when incidence rates are low (as they are in this instance).34  To avoid this problem I 













            (11) 
where Yi is equal to 1 if an individual reports having the presence of a health 
conditions, and 0 otherwise; Xi is a vector of demographic control variables 
accounting for race and sex, AGEi is a vector of dummy variables for age, g(QOBi) is 
a cubic polynomial for quarter of birth cohort (e.g., first quarter of 1917, second 
quarter of 1917 etc.); REGIONi controls for region of residence fixed effects; MOBi 
controls for month of birth fixed effects.35  The explanatory variable of interest is 
                                                 
34 For a more detailed discussion of the failure of the linear probability model in this situation see 
Woolridge (2002), Chapter 15 and Johnston and Dinardo (1997), Chapter 13. 
35 Alternate specifications which include high order polynomials for age and interact age with quarter 




FLUi—a dummy variable indicating whether the individual was affected by the flu 
pandemic in utero.36  F is the logistic function. In this analysis I allow for an arbitrary 
variance-covariance matrix accounting for within group correlation in the errors 
based on the year of birth/survey year cohort.37   
 The specific health outcomes considered in this analysis include heart disease, 
diabetes, kidney disorders.  The selection of these outcomes was guided by two 
factors.  First, as discussed above, they represent those conditions identified in animal 
experiments as having relatively precise predictions regarding the time period of fetal 
insult result in later life health conditions.  Mcmillen and Robinson (2005) provided 
an overview of fetal origins hypothesis and focused on these metabolic and 
cardiovascular outcomes as primary endpoints.  These outcomes are among the most 
costly and deadly conditions for later life health and therefore their ultimate cause is 
of great interest to health professionals.  In addition to the specific chronic conditions, 
this analysis also estimates the effect of decreased fetal health on self-reported health 
status during later life.  
                                                 
36 Throughout this analyis, in-utero flu exposure will be defined at many levels of specificity.  
37 Kloeck (1981) provides a measure of the bias in standard errors in the presence of within group 
correlation in the errors.  In the case where all regressors are fixed within group and all groups have the 
same size, m, the true variance-covariance matrix is ])1(1[)'( 12 ρσ −+− mXX —where ρ  is the 
amount of within group correlation.  Even in the case of groups of differing sizes, [1 + (m-1)ρ] serves 
as an approximate measure of the bias caused by within group correlation (Bertrand 1990).  This bias 
is a function of both the size of the groups and the amount of correlation within the groups.   
In most cases, researchers are concerned with positive within group correlation leading to a 
downward bias in the OLS standard errors. This dataset of repeated cross sections and negative health 
outcomes, however, contains a high level of negative within group correlation. At least a portion of 
this negative correlation is a mechanical result of the construction of the dataset.  Groups with a high 
rate of chronic conditions in early survey years should experience higher mortality rates and as a result 
will appear healthier in later survey years. The mechanical negative correlation is magnified in this 
case by large group sizes—the average size of a year of birth cohort in the data is approximately 9,500.  
Groups of this size mean that even a small amount of negative correlation will lead to a large bias in 
the estimated standard errors. 
  In order to avoid this mechanical negative correlation but still account for correlation within 
year of birth cohorts, I allow for correlation between year of birth and year of survey cohorts.  This 




One concern about this analysis is that there may be gender based differences 
in both the effects of fetal programming and in the presence of selective mortality.  
Mcmillen and Robinson (2005) stated, “there is also a differential impact of early 
nutritional manipulations on male and female offspring in experimental studies in a 
range of animal species.”  Gluckman et al. (2008) reported similar differences in 
outcomes in animal studies.  A further gender based concern is differences in 
selective mortality by sex.  For example, males have a higher rate of heart disease 
than females and therefore may die at younger ages.  Due to the relatively older ages 
that individuals are included in this study, it is possible that these differences in heart 
conditions may generate a downward bias in the estimated effect of in-utero exposure 
to the peak of the flu pandemic.  This magnitude of this bias may vary by sex. Due to 
these factors, I will estimate effects for the full sample and for gender based sub-
samples.38 
There are several important identifying assumptions that are necessary for this 
model to accurately estimate the long-term effect of in-utero exposure to the flu.  
First, I assume that the long term health effects of the flu pandemic are felt solely by 
those exposed to the pandemic in-utero.  A specific concern here is that individuals 
born in time periods after the flu pandemic, but not exposed to the flu in-utero, should 
be no more or less likely to develop these chronic conditions later in life.39   
                                                 
38 Due to sample size concerns, some of these gender based sub samples may return relatively 
imprecise estimates.  This is particularly true for rare conditions such as kidney disorders. 
39 It is possible, however, that there are non-medical responses to the flu that could result in long-term 
health consequences.  For example, some school-age individuals contracted influenza and survived.  
Their sickness may have caused them to acquire less total education in their lifetime.  There is a 
documented connection between education levels and mortality (Lleras-Muney, 2005; Elo and Preston, 
1996; Kitagawa and Hauser, 1973; Grossman and Kaestner, 1997). As a result, the flu could affect 




I also assume that subsequent flu seasons did not substantially affect the in-
utero conditions of immediately surrounding birth cohorts—in particular those 
cohorts following the peak of the pandemic.  Figure 9 shows the sharp increase in 
deaths in 1919 compared to surrounding years.  In addition, as discussed previously, 
the 1918 flu affected the young and healthy to a greater degree than more standard flu 
variants.  
To the test these assumptions I will estimate the health effects of being born in 
leading and lagging cohorts of those affect in-utero by the peak of the 1918 flu 
pandemic.  A lack of an effect for these groups will support the underlying theory that 
the fetal exposure to the flu pandemic is causing the changes in later life health 
outcomes.  
Health Outcome Results 
Medical knowledge of fetal development in humans and animal experiments 
of fetal stress provide explicit predictions concerning the later life health effects of 
decreases in fetal health.  Given this background information, I hypothesize that the 
pattern of results across different conditions should follow the pattern described in 
Table 18. 
Table 19 reports logit estimates of equation (11).  The first row contains 
results for a model identifying exposure to the 1918 pandemic as being born in the 
fourth quarter of 1918, the first quarter of 1919, or the second quarter of 1919.  For 
both the full sample, and for men only there is a statistically significant increase in the 
probability of having heart disease for individuals affected by the peak of the 




being exposed to the flu in-utero is associated with a 0.7 percentage point increase in 
the probability of developing heart disease in later life.  The effect for just men was 
similar in magnitude.  There was no statistically significant effect for women, but this 
may be due to the fact that this is a relatively broad measure of flu exposure that 
cannot precisely define the timing of the increased fetal stress.  The medical literature 
suggests that failing to accurately pinpoint the timing of fetal exposure makes it 
difficult to detect the effects of specific chronic conditions.   
 Defining in-utero flu exposure based on quarter of birth returns more precise 
estimates of the effect of fetal stress on developing certain chronic conditions.  Rows 
(2)-(4) of Table 19 contain estimates for coefficients on dummy variables identifying 
individuals born in the fourth quarter of 1918, the first quarter of 1919, or the second 
quarter of 1919.  The estimates in parentheses are standard errors and those in 
brackets are the marginal effects.  These results show that in-utero exposure to the 
1918 pandemic increases the probability of developing coronary heart disease in later 
life.  For the entire sample, being born in the first quarter of 1919 is associated with 
an approximately 1.1 percentage point in the probability of developing coronary heart 
disease.  This result is statistically significant at the 10 percent level.  The underlying 
prevalence of coronary heart disease for this age group is 10.7 percent, suggesting 
that in-utero exposure to the flu pandemic is associated with a 10.3 percent increase 
in the probability of developing heart disease. For men, being born in the first quarter 
of 1919 increases the probability of developing coronary heart disease by 
approximately 2.2 percentage points, or 18.5 percent.  This result is statistically 




1.1 percentage points or 11.6 percent for those born during the second quarter of 
1919.  This result is also statistically significant at the 5 percent level. 
It is possible that the statistically significant results in Table 19 are due to 
secular factors other than in-utero exposure to the 1918 pandemic.  If this were the 
case, then it is likely that similar results would be found among the surrounding birth 
cohorts.  Table 20 contains a specification of equation (11) with dummy variables 
indicating the quarter of birth for all individuals born between 1917-1920.  In the full 
sample, there are positive and statistically significant results only for the 1st quarter of 
1919—individuals who were in-utero during the pandemic.  There is a negative and 
statistically significant effect for individuals born during the 3rd quarter of 1920.  For 
men, there is a positive and statistically significant result for individuals born during 
the 1st quarter of 1918.  It is unclear why this may be the case, though some medical 
literature does suggest that post-natal exposure to the flu pandemic may have resulted 
in increased rates of coronary heart disease (Azambuja, 2004).  Among women, the 
only statistically significant result is for individuals born during the 2nd quarter of 
1920—those individuals who were affected by the peak of pandemic during the 
earliest months of fetal development. 
Assuming a normal gestation length, individuals born in the first quarter of 
1919 were exposed to the flu during anywhere from the fifth to ninth months in-utero.  
Fetal stress during this period has a detrimental effect on later life coronary health.  
For women, this effect occurs during the second quarter of 1919.  These results are 
consistent with the medical predictions that fetal stress in the mid-to-early stages of 




Table 21 contains results for equation (11) where flu exposure is defined at 
the month of birth level. For both sexes, a statistically significant result is found for 
individuals born in December, 1918.  For men, there are statistically significant 
results for December, 1918 and January, 1919.  For women, there are positive 
statistically significant results for December, 1918, May, 1919 and June 1919.  There 
is also an inexplicable negative and statistically significant result for women born in 
October, 1918.  The results for males are earlier than may be expected based on a full 
term delivery, but it is important to recognize that exposure to the full during 
pregnancy was found to be associated with an increase in pre-term delivery, so these 
individuals may have been exposed earlier in fetal development terms than their birth 
date would suggest.  
The difference in timing between the effects of men and women could be 
caused by several factors.  First, medical research suggests that males and females 
react differently to fetal insults (Gluckman et al., 2008; Mcmillen and Robinson, 
2005).  In addition, as will be discussed later, this difference between may provide 
evidence of attrition in the sample creating a downward bias to the results.  
Suggestive evidence of this may also be found in the divergent results between 
women and men born in June, 1919.  Women have a positive, large, and statistically 
significant estimated effect while men have a large and negative effect.  Though the 
effect for men is not statistically significant, it is similar in magnitude (although 
opposite in sign) to the result for women. 
Table 22 contains the results for equation (11) with diabetes as the outcome of 




reporting diabetes in later life.  Specifically, being born in the second quarter of 1919 
increases the probability of developing diabetes by 19.4 percent.  This result is 
significant at the 5 percent level.  Examining the results by sex, a statistically 
significant effect is found for women born during the second quarter of 1919.  A point 
estimate of similar magnitude is found for men born during this time period, though 
this result is not statistically significant at conventional levels.  Table 23 contains the 
results for a specification containing leading and lagging cohorts of those in-utero 
during the flu.  In addition to individuals born during the 2nd quarter of 1919, These 
results show positive and statistically significant effects for individuals born during 
2nd quarter of 1917 and the 1st quarter of 1920.  While this pattern of results is less 
compelling than the results for heart disease they still provide evidence that in-utero 
exposure to the peak of the flu pandemic affected the likelihood of diabetes in later 
life. 
The results examining the effect by month of birth are contained in Table 24.  
These results show that the effects of flu exposure are driven by individuals born 
during April and May of 1919—those individuals who were in the earliest months of 
fetal development during the peak of the 1918 pandemic. The timing of this effect 
could be troubling for public health policymakers as it is more difficult for nutrition 
and other public health programs aimed at new mothers to effect in-utero conditions 
during the earliest months of pregnancy.  This may suggest a need for general public 





Table 25 contains the estimates for equation (11) with kidney disorders as the 
dependent variable.  In-utero exposure to the flu pandemic increases the probability 
of reporting a kidney disorder later in life.  Individuals born during the fourth quarter 
of 1918 face an approximately 50 percent increase in the probability of having a 
kidney disorder.  Examining the results by sex only finds a statistically significant 
effect for women, though the point estimate for men is of similar magnitude.  Table 
26 contains the results for leading and lagging cohorts of individuals exposed to the 
flu in-utero.  There are no statistically significant effects other than for individuals 
born during the 4th quarter of 1918.  Looking at the results by month of birth in Table 
27 shows that individuals born during the flu pandemic, and therefore exposed 
relatively late in terms of fetal development, are those most affected.  There is also a 
positive and statistically significant effect for men born during April, 1919.  Together, 
these results suggest that increased fetal stress during the last months of a pregnancy 
affects later life kidney health.  This is consistent with the biological fact that the 
majority of kidney development occurs during the last trimester. 
Table 28 contains the results for self-reported health status.  Specifically, it 
contains results for a specification of equation (11) with a dependent variable 
indicating an individual reports being either in “poor” or “fair” health.  For the full 
sample, men only, and women only the broadest measure of flu exposure (being born 
in either the 4th quarter 1918, or the first or second quarters of 1919) is associated 
with a statistically significant increase in the probability of reporting being in poor 
health.  For example, for the full sample, being exposed to the flu pandemic in-utero 




status later in life.  Examining leading and lagging cohorts of those exposed in-utero 
in Table 29, the only positive and statistically significant results are for individuals 
that were exposed to the peak of the flu pandemic in-utero.  There is also a negative 
and statistically significant effect for individuals born during the 3rd quarter of 1920 
and for women only born during the 4th quarter of 1919.  Table 30 contains the results 
for in-utero exposure defined at the month of birth level.  For the full sample, there 
are positive and statistically significant results for individuals born during December, 
1918 ad well as January, February and April of 1919.  For men the results are positive 
and statistically significant for individuals born during December 1918 or January 
1919.  Among women, statistically significant results are found for December, 1918 
as well as February, April, and May 1919. 
In total, these provide a pattern of results that is consistent with the later life 
health conditions being caused by the flu.  Furthermore, the timing of the results 
matches the hypothesized pattern predicted by the medical literature and detailed in 
Table 17. 
 
Attrition in the Sample 
There are two possible sources of attrition that are of concern to this analysis.  
The first source of attrition results from the increased number of miscarriages and 
stillbirths resulting from in-utero flu exposure.  Almond (2006) stated that there was a 
40 percent increase in still-births during the October-December, 1918 period.  It is 
possible that this resulted in an increase in the average general health of surviving 




babies that were of marginal health.  It is likely however, that any bias in the 
estimated causal effect of in-utero flu exposure on later life health generated by this 
increase in average general health would be downward in nature.  
A second potential source of bias comes from individuals with chronic 
conditions dying before they were surveyed in later life—raising the average health of 
the remaining cohort.  This “survivor bias” would cause adults surveyed by the NHIS 
in later life to appear healthier on average as a result of their in-utero flu-exposure.   
As a test for the presence of this survivor bias, I re-estimated equation (11) 
with coronary heart disease as the outcome of interest using males in three sub-
samples of differing ages.  If attrition were affecting the results, the estimated 
coefficients should decrease across these samples, with the lower probabilities 
resulting from mortality increasing the average health of surviving age groups.  
Figure 10 displays the marginal effects and 95 percent confidence intervals for males 
born during the first quarter of 1919—the time period showing the largest effect for 
males in Table 19.  There is a clear downward trend in the marginal effects across the 
three samples.  In addition, a statistically significant effect is only found for males in 
the youngest age group.  I conducted similar analyses for kidney disease and diabetes 
but because of large standard errors generated by low incidence rates, there was no 
clear pattern in the data.   
A sensible interpretation of this pattern of decreasing estimates for older 
individuals is attrition among the cohorts exposed to the flu.  Older individuals have a 
decreased probability of reporting chronic health conditions because each year 




from the group increases the average health of the remaining cohort.  As a result of 
the advanced age of this sample, many of the results above should be viewed as lower 
bound estimates of the health effects of fetal stress related to the flu pandemic. 
Effect on Education 
A primary finding of Almond (2006) was a decrease in both years of total 
education and the likelihood of graduating high school for individuals born in 1919.  
Figures 11 and 12 show the average highest grade completed and the percentage 
graduating high school in the sample by year of birth.  Similar to the graphical 
evidence in Almond, it appears that there may be some effect for those born during 
1919.  Before and after this year there is a clear upward trend in education outcomes.  
Examining educational attainment by quarter of birth, the potential effect of the flu is 
less clear due to a number of other factors correlated with quarter of birth that affect 
education levels.40   
In order to test the effect of in-utero flu exposure on educational outcomes, I 
estimated a specification of equation (11) with a dependent variable equal to 1 if the 
individual was a high-school graduate.  I also estimated an ordinary least squares 
specification with the highest grade completed as the dependent variable.  
 Table 31 reports the estimates for effect of in-utero exposure to the flu 
pandemic on both the change in the probability of graduating high school and the 
highest grade completed.  Columns (1) – (3) contain the OLS estimates for all NHIS 
respondents, men, and women with the highest grade completed as the dependent 
                                                 
40 To some extent this fact should be expected since previous work has demonstrated a strong quarter 
of birth effect on education (Angrist and Krueger, 1991).  This increases the signal-to-noise ratio 




variable.  Row (1) contains results for flu exposure defined as being born in either the 
fourth quarter of 1918 or the first or second quarters of 1919.  There are no 
statistically significant results on highest grade completed or for graduating high 
school for flu exposure defined in this manner.  Rows (2) – (4) contain the results for 
flu exposure at the quarter of birth level.  Similar to the broader measure of exposure 
there are no statistically significant estimates at this level of exposure. Table 32 
contains estimates for the leading and lagging quarters of birth.  As can be seen from 
the table, several of these quarters of birth return positive and statistically significant 
results for both highest grade level completed and probability of being a high school 
graduate.  This includes the second and third quarters of 1918—the two quarters 
immediately preceding the peak of the pandemic.   
 Table 33 provides estimates examining the effect of in-utero flu exposure on 
educational attainment using month of birth as the level of exposure provides limited 
evidence of a negative effect.  For example, men born in May 1919 and women born 
during March 1919 return a negative and statistically significant decrease in the 
number of grades completed.  For men born in December, 1918 there is a statistically 
significant decrease in the probability of graduating high school.   
The lack of a consistent pattern of results provides limited evidence from this 
data that in-utero exposure to the flu decreased educational attainment. This stands in 
contrast to the effect of the flu on education found in Almond (2006).  This is likely a 
result of the NHIS being a less appropriate dataset for estimating the effect of the flu 
pandemic on educational outcomes.  Compared to the PUMS sample used by 




general older.  Due to these factors, it should be unsurprising that the estimates 
related to education are far less pr ecise.  
 
Conclusion 
The results of this analysis suggest that in-utero exposure to the 1918 flu 
pandemic had long lasting negative health consequences.  Depending on the period of 
fetal development during which exposure occurred, individuals have a higher 
probability of developing coronary heart disease, diabetes, kidney disorders, or being 
in poor health.  There is limited evidence from this analysis that exposure to the flu 
in-utero also affects education levels.  
The strong relationship between in-utero stress during certain periods of fetal 
development and specific conditions in later life shows that the duration of the event 
used for quasi-experimental variation in fetal conditions is critical to analyses 
involving specific diseases.  When flu exposure was defined over several quarters of 
birth, it is not possible to pinpoint stress to particular periods of fetal development.  
As a result, many of the individuals who received the “treatment” of fetal stress 
should not be expected to develop particular conditions. For example, the nutrition 
delivery system of the fetus is almost fully developed by the last trimester.  
Individuals experiencing fetal stress during this time period should not be expected to 
have a higher probability of developing diabetes in later life.  Grouping all individuals 
into one large category (including both “treated” and “untreated” individuals with 
respect to certain conditions) limits the ability of the analysis to detect any effect from 




its broadest level and diabetes is the dependent outcome of interest there was no 
statistically significant effect.   When flu exposure is defined using particular quarters 
of birth, however, there is an approximately 20 percent increase in the probability of 
developing diabetes for individuals exposed to the flu during the first months of 
pregnancy. 
The short duration of the 1918 pandemic allows researchers to attribute flu 
exposure to these particular time periods of development.  Identification strategies 
using long-lasting events such as the Chinese famine or the Siege of Leningrad, on 
the other hand, are hampered by their inability to determine particular time periods of 
fetal stress.  The long duration of these events is at least one reason that previous 
attempts to document disease specific outcomes of the fetal origins hypothesis have 
been more mixed than these results.    
While the long term health impact of the flu pandemic is interesting, the 
insight gained by this analysis can be beneficial in understanding a number of 
important questions regarding the effects of poor in-utero conditions from other 
sources.  Generalizing the results of this analysis to all cases of fetal stress raises a 
question of external validity.  There is biological evidence, however, that the effect of 
in-utero flu exposure is similar to other complications.  Irving et al. (2000) found that 
in-utero exposure to influenza resulted in a higher rate of complications in pregnancy.  
This decrease in fetal health provides a connection between the fetal origins 
hypothesis and the 1918 pandemic.41  Taken together, the animal studies, cross 
                                                 
41 The underlying theory of this paper is that the increase in physical stress from in-utero flu exposure 
is responsible for the changes in later life health.  It is also possible, however, that a general increase in 





sectional analysis of humans, and the results of this analysis suggest that maternal 
health during pregnancy is an important contributor to the long-term health of their 
offspring.   
The long term effects of decreased fetal health can generate significant 
societal costs.  The management of chronic conditions makes up an increasing share 
of expenditures in the Medicare program.42  In particular, heart disease and diabetes 
are primary cost drivers.  For example, 42 percent of the top quartile of Medicare 
patients in terms of spending have coronary heart disease.  Additionally, 32 percent of 
these high cost patients suffer from diabetes (Congressional Budget Office, 2005).  A 
RAND study states, “chronic illnesses such as heart disease, cancer, and diabetes are 
expensive to treat. As a consequence, the relatively small proportion of Medicare 
beneficiaries with such diseases account for a disproportionate share of Medicare 
spending — perhaps as much as three-quarters of the total” (RAND, 2005).43  To the 
degree that in-utero stress increases the incidence of these conditions it also generates 
higher Medicare spending. 
Beyond simply the impact on medical spending, the presence of chronic 
conditions leads to a lower quality of life, work effort, and productivity.  Almond 
(2006) found that in-utero exposure to the flu led to a 20 percent increase in disability 
and a 5-9 percent decrease in wages.  These results are similar to previous estimates 
of the effect of chronic conditions and health status on labor supply.  Bartel and 
Taubman (1979) found statistically and economically significant decreases in labor 
                                                 
42 Due to their age, early all individuals affected by the flu that are considered in this study qualify for 
Medicare benefits.   
43 While the higher likelihood of an early death for individuals with these chronic conditions does limit 
their effect on total Medicare costs, RAND still estimates that coronary heart disease and diabetes 




force participation and earnings for individuals with a variety of chronic conditions 
including heart disease.  Mitchell (1990) states, “[p]oor health is associated with 
reduced hours of work, lower wage rates, early retirement and disability transfer 
programs” (p. 928).  These lower work levels and earnings add another dimension to 
the social cost of chronic conditions and the importance of fully understanding their 
origins.  
While these health benefits must be discounted due to their accrual so long 
after birth, it is clear that they represent a valuable and previously ignored benefit of 
improved fetal conditions.  Several federal, state, and private programs attempt to 
improve access to prenatal care—particularly for underserved populations.  For 
example, Medicaid now provides prenatal care services.   In addition, the Women, 
Infants, and Children (WIC) program is explicitly intended to improve nutrition for 
pregnant women.  There is often debate about the net efficacy of these pre-natal 
programs.  Evaluations of their benefit, however, fail to consider the potential long 
term health benefits (Evans and Lien, 2005; Wayne et al., 1998; Currie and Gruber, 
1996; Devaney et al., 1992).  Instead, these programs are traditionally judged based 
on immediate infant health concerns such as birthweight, 28 day readmission rates, 
and infant mortality.  The results for this study show that long term health benefits 
should also be a factor in these evaluations.  This will provide a more accurate 










Reported ICD-9 Codes for Vioxx Prescriptions 
 Condition Percent of Vioxx Recipients 
1. Other and unspecified arthropathies 43.2 
2. Other and unspecified disorders of back 20.9 
3. Other and unspecified disorders of joint 14.7 
4. Intervertebral disc disorders 8.35 
5. Osteoarthrosis and allied disorders 6.2 
Source: Medical Expenditure Panel Survey 1998-2004   
 
Table 2 




Non-Vioxx Recipients  
Age 55-65  
Age 59.75 59.51 
% Female 66.71 52.91 
% HS Grad 77 73.4 
% Bachelors 21.9 22.7 
% White 73.5 74 
% Black 10.4 12.4 
Health Status 2.99 2.61 
% Working 53 58.6 
Source: Medical Expenditure Panel Survey 1998-2004 
 
Table 3 
Descriptive Statistics for Individuals with Joint Conditions 
 Ever Taken Vioxx Never Taken Vioxx  
Age 59.68 56.02 
% Female 68.19 61.87 
% HS Grad 72.55 64.35 
% Bachelors 17.93 15.61 
% White 71.69 73.13 
% Black 12.49 13.98 
Health Status 3.05 2.88 
% Working 43.38 43.60 










OLS Estimates of Labor Supply, MEPS 1998-2004 
 
Parameter Estimates (Standard Errors) 
















































































































N 27,883 37,290 66,487 
Entries represent the estimated coefficients from a linear probability model.  The 
dependent variable is a binary variable equal to one if an individual reports 
employment during the MEPS round.  The last two rows report the linear 
combination and (standard error) for a binary variable documenting a reported Vioxx 
prescription and this variable interacted with a binary variable indicating the presence 
of a chronic joint or back condition.  Unreported covariates control for a cubic age 
trend, insurance status, and MEPS round.  Regressions are weighted using MEPS 
longitudinal weights. Standard errors are clustered at the individual level.   
* Significant at the .10 level   
** Significant at the .05 level   







Fixed Effect Estimates of Labor Supply, MEPS 1998-2004 
 
Parameter Estimates (Standard Errors) 


















































































N 6,706 8,581 14,439 
N*T 22,509 30,049 53,421 
Entries represent the estimated coefficients from a fixed effect linear probability model.  
The dependent variable is a binary variable equal to one if an individual reports 
employment during the MEPS round.  The last four rows report the linear combination 
and (standard error) for a binary variable documenting a reported Vioxx prescription 
and this variable interacted with a binary variable indicating the presence of a chronic 
joint or back condition.  Unreported covariates control for a cubic age trend and MEPS 
round. Regressions are weighted using MEPS longitudinal weights. Standard errors are 
clustered at the individual level.   
* Significant at the .10 level   
** Significant at the .05 level   







Fixed Effects Estimates of Labor Supply, MEPS 1998-2004 
 
Parameter Estimates (Standard Errors) 
 Males Females 




















































































































































N 3,106 3,976 6,529 3,600 4,605 7,910 
N*T 10,414 13,950 24,122 12,095 16,099 29,299 
Entries represent the estimated coefficients from a fixed effect linear probability 
model.  The dependent variable is a binary variable equal to one if an individual 
reports employment during the MEPS round.  The last four rows report the linear 
combination and (standard error) for a binary variable documenting a reported Vioxx 
prescription and this variable interacted with a binary variable indicating the presence 
of a chronic joint or back condition. Unreported covariates control for a cubic age 
trend and MEPS round. Regressions are weighted using MEPS longitudinal weights. 
Standard errors are clustered at the individual level.   
* Significant at the .10 level   
** Significant at the .05 level   







Fixed Effects Estimates of Male Labor Supply, MEPS 1998-2004 
 
Parameter Estimates (Standard Errors) 
 Physical Work Ever Never Report Physical Work 






























































































N 1,040 1,224 1,497 2,066 www2,752 5,032 
N*T 3,498 4,324 5,517 6,916 9,626 18,605 
Entries represent the estimated coefficients from a fixed effect linear probability model.  
Columns (1) – (3) contain estimates for males that report an occupation code for a job 
requiring a large amount of physical labor in at least one MEPS round.  Footnote 18 describes 
this selection process. Columns (4) – (6) contain results for males that never report an 
occupation requiring primarily physical labor. The dependent variable is a binary variable 
equal to one if an individual reports employment during the MEPS round.  The last two rows 
report the linear combination and (standard error) for a binary variable documenting a 
reported Vioxx prescription and this variable interacted with a binary variable indicating the 
presence of a chronic joint condition.  Unreported covariates control for a cubic age trend and 
MEPS round.  Regressions are weighted using MEPS longitudinal weights Standard errors 
are clustered at the individual level.   
* Significant at the .10 level   
** Significant at the .05 level   







Fixed Effects Estimates of Celebrex on Labor Supply, MEPS 1998-2004 
 
Parameter Estimates (Standard Errors) 
 Males Females 










































































































CELEBREXt-1 + CELEBREXt-1+JOINT 



























CELEBREXt-1 + CELEBREXt-1+BACK 













        
N 3,106 3,976 6,529 3,600 4,605 7,910 
N*T 10,414 13,950 24,122 12,095 16,099 29,299 
Entries represent the estimated coefficients from a fixed effect linear probability model.  The 
dependent variable is a binary variable equal to one if an individual reports employment 
during the MEPS round.  The last four rows report the linear combination and (standard 
error) for a binary variable documenting a reported Celebrex prescription and this variable 
interacted with a binary variable indicating the presence of a chronic joint condition.  
Unreported covariates control for a cubic age trend and MEPS round. Regressions are 
weighted using MEPS longitudinal weights.  Standard errors are clustered at the individual 
level.   
* Significant at the .10 level 
** Significant at the .05 level   








Conditional Logit Estimates of Labor Supply, MEPS 1998-2004 
 
Parameter Estimates (Standard Errors) [Odds Ratios] 
 Males Females 




































































































N 407 662 508 766 
N*T 1,495 2,503 1,893 2,908 
Entries represent the estimated coefficient, (standard error), and [odds ratio] from a 
fixed effect conditional logit model.  The dependent variable is a binary variable 
equal to 1 if an individual reports working at any time during the MEPS round. 
Individuals who report always working or never working are not included in the 
analysis. The last two rows report the linear combination for a binary variable 
documenting a reported Vioxx prescription and this variable interacted with a 
binary variable indicating the presence of a chronic joint condition.  Unreported 
covariates control for a cubic age trend and MEPS round. Standard errors are 
clustered at the individual level.   
* Significant at the .10 level   
** Significant at the .05 level   








Fixed Effects Estimates of Labor Supply, MEPS 1998-2004 
 
Parameter Estimates (Standard Errors) 
 Males Females 
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N 3,246 3,779 4,126 3,246 3,779 4,126 
N*T 12,901 14,982 17,316 12,901 14,982 17,316 
Entries represent the estimated coefficients from a fixed effect linear probability model.  The 
first three columns include individuals that report an occupation code for a job requiring a 
large amount of physical labor in at least one MEPS round.  Footnote 18 describes this 
selection process.  The dependent variable is a binary variable equal to one if an individual 
reports employment during the MEPS round.  The last two rows report the linear combination 
and (standard error) for a binary variable documenting a reported Lipitor or Nexium 
prescriptions and this variable interacted with a binary variable indicating the presence of 
high cholesterol or acid reflux disease, respectively.  Unreported covariates control for a 
cubic age trend and MEPS round.  Regressions are weighted using MEPS longitudinal 
weights. Standard errors are clustered at the individual level.   
* Significant at the .10 level   
** Significant at the .05 level   







Fixed Effects Estimates of Vioxx on Hours Worked, MEPS 1998-2004 
 
Parameter Estimates (Standard Errors) 
 Males Females 




















































































































































N 3,106 3,976 6,529 3,600 4,605 7,910 
N*T 10,414 13,950 24,122 12,095 16,099 29,299 
Entries represent the estimated coefficients from a fixed effect ordinary least squares model.  
The dependent variable is the usual weekly hours worked reports in the MEPS.  The last four 
rows report the linear combination and (standard error) for a binary variable documenting a 
reported Vioxx prescription and this variable interacted with a binary variable indicating the 
presence of a chronic joint or back condition.  Unreported covariates control for a cubic age 
trend and MEPS round.  Regressions are weighted using MEPS longitudinal weights 
Standard errors are clustered at the individual level.   
* Significant at the .10 level   
** Significant at the .05 level   














Fixed Effects Estimates of Labor Supply, MEPS 2004-05 
Both Sexes, Age 55-75 
 



























Entries represent the estimated coefficients from a fixed effect linear probability model.  The 
dependent variable is a binary variable equal to one if an individual reports employment during the 
MEPS round.  The last two rows columns report the linear combination and (standard error) for a 
binary variable documenting a reported Vioxx prescription and this variable interacted with a 
binary variable indicating the presence of a chronic joint or back condition.  Unreported covariates 
control for a cubic age trend and MEPS round. Regressions are weighted using MEPS longitudinal 
weights. Standard errors are clustered at the individual level.   
  * Significant at the .10 level  ** Significant at the .05 level   *** Significant at the .001 level 
 
Table 13 
Fixed Effects and IV Estimates of Effect of Vioxx on Labor Supply 
MEPS, Panel 9, 2004-05, Age 55-75 
 
Parameter Estimates (Standard Errors) 
 Reduced Form 2SLS 
 (1) (2) (3) 
 Results of Working on 
Remove 
First Stage Results of 
Vioxx on Remove 
IV Results of Working 






VIOXX   0.416* 
(0.234) 
N 2,725 2,725 2,725 
N*T 12,321 12,321 12,321 
Entries in the table represent the estimated coefficients and standard errors from the linear 
probability IV model.  Unreported covariates also include a cubic age trend and dummy 
variables for MEPS rounds.  Regressions are weighted using MEPS longitudinal weights 
Standard errors are clustered at the individual level.   







Fixed Effects and IV Estimates of Effect of COX-2 Inhibitors on Labor Supply 
MEPS, Panel 9, 2004-05, Age 55-75 
 
Parameter Estimates (Standard Errors) 
 Reduced Form 2SLS 
 (1) (2) (3) 
 Results of Working on 
Remove 
First Stage Results of 
COX-2 on Remove 
IV Results of Working 






VIOXX   0.237* 
(0.133) 
N 2,725 2,725 2,725 
N*T 12,321 12,321 12,321 
Entries in the table represent the estimated coefficients and standard errors from the linear 
probability IV model.  Unreported covariates also include a cubic age trend and dummy 
variables for MEPS rounds.  Regressions are weighted using MEPS longitudinal 
weights Standard errors are clustered at the individual level.   





Fixed Effects and IV Estimates of the Effect of COX-2 Inhibitors on Labor Supply 
MEPS, Panel 9, 2004-05, Age 55-75 
 
Parameter Estimates (Standard Errors) 
 Reduced Form   2SLS 
 (1) (2) (3) 
 Results of Working 
on Remove 
First Stage Results of 
COX-2 on Remove 








    
VIOXX   9.57 
(1159.1) 
N 2,725 2,725 2,725 
N*T 12,321 12,321 12,321 
Entries in the table represent the estimated coefficients and standard errors from the linear 
probability IV model.  Unreported covariates also include a cubic age trend and dummy 
variables for MEPS rounds.  Regressions are weighted using MEPS longitudinal 
weights. Standard errors are clustered at the individual level.   










Fixed Effects and IV Estimates of Labor Supply 
MEPS, Panel 9, 2004-05, Age 55-75 
 
Parameter Estimates (Standard Errors) 
 Reduced Form 2SLS 
 (1) (2) (3) 
 Results of Working 
on Remove 
First Stage Results of 
COX-2 on Remove 








    
COX-2   -3.8 
(17.18) 
N 2,725 2,725 2,725 
N*T 12,321 12,321 12,321 
Entries in the table represent the estimated coefficients and standard errors from the linear 
probability IV model.  Unreported covariates also include a cubic age trend and dummy 
variables for MEPS rounds.  Regressions are weighted using MEPS longitudinal 
weights Standard errors are clustered at the individual level.   









Adults aged 55 to 90, 1982 to 2002 NHIS and 1980 to 2000 Census 
 NHIS 1980-2000 5% PUMS 
% Female 56.9 56.3 
% Black 11.1 8.1 
% Hispanic 6.2 4.3 
% High School Graduate 63.1 62.8 
% College Graduate 15.8 13.6 
% Married 60.1 62.8 














Hypothesized Timing of In-utero Influenza Exposure on Health Outcomes 
 
Quarter of Birth Approximate Trimester of 
Exposure  
Expected Conditions 
4th Quarter, 1918 3rd Trimester Kidney Disorders 
1st Quarter, 1919 2nd Trimester* Heart Conditions 
2nd Quarter, 1919 1st Trimester Heart Conditions 
Metabolic Disorders 
*This approximate time period of exposure assumes a full term delivery.  Medical 
evidence suggests that exposure to the flu pandemic was associated with higher rates 
of preterm delivery. This may cause some of these anticipated effects to occur in 






Logit Estimates of Effect of Flu Exposure on Heart Disease, Adults aged 55 to 90, 1982 to 
2002 NHIS 
 
Parameter estimates (standard errors) [Marginal Effect] 






mean dep. var. =   0.107 
Men 
n= 165,308 


































































Entries in the table represent the estimated coefficient, standard errors, and marginal effects 
from a logit model.  Row (1) contains the results from a specification identifying flu 
exposure from being born in the 4th quarter of 1918, or the 1st or 2nd quarters of 1919.  Rows 
(2)-(4) contain the results from a specification with dummy variables indicating the 
particular quarters of birth.  Other covariates include dummy variables for age, region, 
month of birth, sex, a cubic quarter of birth trend, race, and ethnicity. Standard errors are 
clustered on year of birth/year of survey cohorts to allow for within group correlation.  












Logit Estimates of Effect of Flu Exposure on Heart Disease 
Adults aged 55 to 90, 1982 to 2002 NHIS 
 
Parameter estimates (standard errors) [Marginal Effect] 























[-0.006]         
-0.043 
(0.074) 
[-0.004]     
-0.077 
(0.063) 









[-0.002]          
0.031 
(0.059) 
[0.003]     
-0.067 
(0.06) 








(0.043)   
[-0.002]   
0.028 
(0.06) 
[0.003]      
-0.061 
(0.075) 








(0.07)   
[0.005]   
0.001 
(0.01) 
[0.0001]      
0.116 
(0.082) 









[0.008]     
0.181** 
(0.065) 
[0.02]      
0.004 
(0.087) 









[-0.0001]     
-0.015 
(0.081)  
[-0.002]    
0.017 
(0.053) 









[-0.005]     
-0.223** 
(0.086) 
[-0.021]    
0.091 
(0.071) 









[0.006]      
0.129 
(0.08) 












[0.011]      
0.2** 
(0.084) 
[0.023]      
0.045 
(0.074) 









[0.003]      
-0.06 
(0.09) 
[-0.006]    
0.118* 










[-0.002]     
0.066 
(0.065) 
[0.007]      
-0.105 
(0.083) 









[0.003]     
0.058 
(0.115) 
[0.006]      
0.001 
(0.108) 
[0.0001]      








(0.066)    
[0.009]   
(0.08) 
[0.014]      
(0.078) 









[-0.002]     
0.06 
(0.078) 










-0.112**   
(0.055) 
[-0.01]     
0.003 
(0.074)   












[-0.005]    
-0.049 
(0.089) 




Entries in the table represent the estimated coefficient, standard errors, and marginal effects from a 
logit model.  Other covariates include dummy variables for age, region, month of birth, sex, a cubic 
quarter of birth trend, race, and ethnicity. Standard errors are clustered on year of birth/year of 
survey cohorts to allow for within group correlation.  













































Logit Estimates of Effect of Flu Exposure on Heart Disease  
Adults aged 55 to 90, 1982 to 2002 NHIS 
 
Parameter estimates (standard errors) [Marginal Effect] 






mean dep. var. =   0.107 
Men 
n= 165,308 
mean dep. var. =  0.124 
Women 
n= 218,477 








































































































































Entries in the table represent the estimated coefficient, standard errors, and marginal effects from a logit 
model.  Other covariates include dummy variables for age, region, month of birth, sex, a cubic quarter 
of birth trend, race, and ethnicity. Standard errors are clustered on year of birth/year of survey cohorts 
to allow for within group correlation.  



















Logit Estimates of Effect of Flu Exposure on Diabetes, Adults aged 55 to 90, 1982 to 2002 NHIS 
 
Parameter estimates (standard errors) [Marginal Effect] 






mean dep. var. =   0.067 
Men 
n= 165,308 
mean dep. var. =  0.064 
Women 
n= 218.477 





























































Entries in the table represent the estimated coefficient, standard errors, and marginal effects from a 
logit model.  Row (1) contains the results from a specification identifying flu exposure from being 
born in the 4th quarter of 1918, or the 1st or 2nd quarters of 1919.  Rows (2)-(4) contain the results 
from a specification with dummy variables indicating the particular quarters of birth.  Other 
covariates include dummy variables for age, region, month of birth, sex, a cubic quarter of birth 
trend, race, and ethnicity. Standard errors are clustered on year of birth/year of survey cohorts to 
allow for within group correlation.  
























Logit Estimates of Effect of Flu Exposure on Diabetes 
Adults aged 55 to 90, 1982 to 2002 NHIS 
 
Parameter estimates (standard errors) [Marginal Effect] 






mean dep. var. =   0.067 
Men 
n= 165,308 
mean dep. var. =  0.064 
Women 
n= 218.477 







0.021    
(0.084) 
     [0.001] 
0.094 
(0.105) 
[0.005]      
0.032 
(0.115) 







0.199**   
(0.077) 
[0.012]     
0.331*** 
(0.092) 
[0.02]      
0.09 
(0.105) 









[-0.003]    
0.074 
(0.109) 
[0.004]      
-0.068 
(0.095) 









 [0.001]     
-0.047 
(0.13) 
[-0.002]     
0.061 
(0.129) 









 [0.005]     
0.008 
(0.122) 
[0.0004]      
0.138 
(0.09) 









[0.002]      
0.088 
(0.111) 
[0.005]      
-0.004 
(0.084) 












[0.01]      
0.118 
(0.086)  









[-0.0002]     
0.053 
(0.123) 
 [0.003]     
-0.045 










[-0.001]     
-0.114 
(0.141) 
[-0.006]     
0.054 
(0.137) 









[0.014]      
0.198 
(0.149) 
 [0.012]     
0.246** 
(0.125) 









[-0.0003]     
-0.054 
(0.142) 
[-0.003]     
0.027 
(0.107) 









[0.002]      
0.066 
(0.124) 
[0.004]      
0.01 
(0.1) 






























































(0.1)     
[-0.002] 
Entries in the table represent the estimated coefficient, standard errors, and marginal effects from a 
logit model.  Other covariates include dummy variables for age, region, month of birth, sex, a cubic 
quarter of birth trend, race, and ethnicity. Standard errors are clustered on year of birth/year of survey 
cohorts to allow for within group correlation.  














































Logit Estimates of Effect of Flu Exposure on Diabetes 
Adults aged 55 to 90, 1982 to 2002 NHIS 
 
Parameter estimates (standard errors) [Marginal Effect] 






mean dep. var. =   0.067 
Men 
n= 165,308 
mean dep. var. =  0.064 
Women 
n= 218,477 








































































































































Entries in the table represent the estimated coefficient, standard errors, and marginal effects from a logit 
model.  Other covariates include dummy variables for age, region, month of birth, sex, a cubic quarter 
of birth trend, race, and ethnicity. Standard errors are clustered on year of birth/year of survey cohorts 
to allow for within group correlation.  




















Logit Estimates of Effect of Flu Exposure on Kidney Disorders, Adults aged 55 to 90, 1982 to 2002 
NHIS 
 
Parameter estimates (standard errors) [Odds ratios] 






mean dep. var. =  0.006 
Men 
n= 141,855 
mean dep. var. =  0.005 
Women 
n= 183,632 





























































Entries in the table represent the estimated coefficient, standard errors, and marginal effects from a 
logit model.  Row (1) contains the results from a specification identifying flu exposure from being 
born in the 4th quarter of 1918, or the 1st or 2nd quarters of 1919.  Rows (2)-(4) contain the results 
from a specification with dummy variables indicating the particular quarters of birth.  Other 
covariates include dummy variables for age, region, month of birth, sex, a cubic quarter of birth 
trend, race, and ethnicity. Standard errors are clustered on year of birth/year of survey cohorts to 
allow for within group correlation.  






















Logit Estimates of Effect of Flu Exposure on Kidney Disease 
Adults aged 55 to 90, 1982 to 2002 NHIS 
 
Parameter estimates (standard errors) [Marginal Effect] 






mean dep. var. =  0.006 
Men 
n= 141,855 
mean dep. var. =  0.005 
Women 
n= 183.632 









[-0.001]     
-0.128 
(0.435) 
[-0.0001]     
-0.125 
(0.261) 
























 [-0.001]   
-0.044 
(0.368) 
[-0.0001]     
-0.247 
(0.236) 












[0.001]      
-0.273 
(0.385) 









[0.001]      
0.119 
(0.453) 
[0.0005]      
0.247 
(0.265) 









 [0.002]  
0.109 
(0.477) 
[0.0004]      
0.465 
(0.323) 









[-0.001]    
-0.579 
(0.455) 
[-0.002]     
-0.206 
(0.353) 









[0.002]   
0.398 
(0.362) 
 [0.002]     
0.419* 













[0.0001]      
-0.177 
(0.321) 









[0.001]      
0.41 
(0.324) 
 [0.002]     
0.033 
(0.335) 









[0.001]      
-0.069 
(0.319) 
 [-0.0002]    
0.218 
(0.232) 
[0.001]      









[-0.0003]    
(0.364) 
[-0.001]     
(0.22) 









[-0.001]     
-0.158 
(0.432) 
[-0.001]     
-0.322 
(0.342) 







































 [-0.002]   
-0.662 
(0.727) 




Entries in the table represent the estimated coefficient, standard errors, and marginal effects from a logit 
model.  Other covariates include dummy variables for age, region, month of birth, sex, a cubic quarter 
of birth trend, race, and ethnicity. Standard errors are clustered on year of birth/year of survey cohorts 
to allow for within group correlation.  












































Logit Estimates of Effect of Flu Exposure on Kidney Disease 
Adults aged 55 to 90, 1982 to 2002 NHIS 
 
Parameter estimates (standard errors) [Marginal Effect] 






mean dep. var. =  0.006 
Men 
n= 141,855 
mean dep. var. =  0.005 
Women 
n= 183,632 








































































































































Entries in the table represent the estimated coefficient, standard errors, and marginal effects from a logit 
model.  Other covariates include dummy variables for age, region, month of birth, sex, a cubic quarter 
of birth trend, race, and ethnicity. Standard errors are clustered on year of birth/year of survey cohorts 
to allow for within group correlation.  


















Logit Estimates of Effect of In-Utero Flu Exposure on Poor Health, Adults aged 55 to 90, 1982 to 
2002 NHIS 
 
Parameter estimates (standard errors) [Odds ratios] 






mean dep. var. =  0.265 
Men 
n= 165,308 
mean dep. var. =  0.262 
Women 
n= 218,477 





























































Entries in the table represent the estimated coefficient, standard errors, and marginal effects from a 
logit model.  Row (1) contains the results from a specification identifying flu exposure from being 
born in the 4th quarter of 1918, or the 1st or 2nd quarters of 1919.  Rows (2)-(4) contain the results from 
a specification with dummy variables indicating the particular quarters of birth.  Other covariates 
include dummy variables for age, region, month of birth, sex, a cubic quarter of birth trend, race, and 
ethnicity. Standard errors are clustered on year of birth/year of survey cohorts to allow for within 
group correlation.  
















Logit Estimates of Effect of Flu Exposure on Poor Health 
Adults aged 55 to 90, 1982 to 2002 NHIS 
 
Parameter estimates (standard errors) [Marginal Effect] 






mean dep. var. =  0.265 
Men 
n= 165,308 
mean dep. var. =  0.262 
Women 
n= 218,477 









[-0.003]     
0.026 
(0.05) 
[-0.005]     
-0.013 
(0.053) 









[0.002]      
0.004 
(0.058) 
[0.001]      
0.012 
(0.048) 









[0.004]      
0.011 
(0.074) 
[0.002]      
0.027 
(0.034) 









[0.0004]      
-0.043 
(0.057) 
[-0.008]     
0.037 
(0.057) 









[-0.004]     
-0.072 
(0.056) 
[-0.013]     
0.014 
(0.043) 









 [-0.001]   
0.052 
(0.047) 
[0.01]      
-0.046 
(0.048) 












 [-0.001]    
0.004 
(0.051) 












[0.005]      
0.117** 













[0.021]      
0.057 
(0.058) 









[0.018]      
0.045 
(0.065) 
 [0.009]     
0.13** 
(0.05) 












[-0.012]     
0.006 
(0.048) 









 [-0.01]   
0.004 
(0.0516) 
 [0.001]     
-0.101* 
(0.055) 









[0.005]      
0.064 
(0.065) 
 [0.012]    
-0.006 
(0.061) 















































(0.052)     
[-0.003] 
Entries in the table represent the estimated coefficient, standard errors, and marginal effects from a logit 
model.  Other covariates include dummy variables for age, region, month of birth, sex, a cubic quarter 
of birth trend, race, and ethnicity. Standard errors are clustered on year of birth/year of survey cohorts 
to allow for within group correlation.  













































Logit Estimates of Effect of Flu Exposure on Poor Health 
Adults aged 55 to 90, 1982 to 2002 NHIS 
 
Parameter estimates (standard errors) [Marginal Effect] 







mean dep. var. =  0.265 
Men 
n= 165,308 
mean dep. var. =  0.262 
Women 
n= 218,477 








































































































































Entries in the table represent the estimated coefficient, standard errors, and marginal effects from a logit 
model.  Other covariates include dummy variables for age, region, month of birth, sex, a cubic quarter 
of birth trend, race, and ethnicity. Standard errors are clustered on year of birth/year of survey cohorts 
to allow for within group correlation.  











Entries in Column (1)-(3) represent the estimated coefficients and standard errors from an ordinary 
least squares regression.  Entries columns (4)-(6) represent the estimated coefficient, standard errors, 
and marginal effects from a logit model.  Row (1) contains the results from a specification identifying 
flu exposure from being born in the 4th quarter of 1918, or the 1st or 2nd quarters of 1919.  Rows (2)-
(4) contain the results from a specification with dummy variables indicating the particular quarters of 
birth.  Other covariates include dummy variables for age, region, month of birth, sex, a cubic quarter 
of birth trend, race, and ethnicity. Standard errors are clustered on year of birth/year of survey cohorts 
to allow for within group correlation.  

















Estimates for Educational Attainment, Adults aged 55 to 90, 1982 to 2002 NHIS 
 
Parameter estimates (standard errors) [Marginal Effect] 







































































-0.009   
(0.02) 
[-0.002]     
















0.00001   
(.034) 

















-0.012   
(0.041) 

















-0.016   
(0.04) 













Estimates for Educational Attainment, Adults aged 55 to 90, 1982 to 2002 NHIS 
 
Parameter estimates (standard errors) [Marginal Effect] 








































































(0.118)      
-0.079 
(0.108)     
0.143 
(0.157)      
0.029   
(0.039) 
 [0.007]     
-0.016 
(0.078) 
 [-0.004]    
0.061 
(0.043) 







0.114   
(0.114)     
0.19 
(0.153)      
0.054 
(0.129)      
0.022   
(0.047) 
[0.005]      
0.111 
(0.081) 
[0.025]      
-0.049 
(0.063) 








(0.136)    
0.188 
(0.25)      
-0.068 
(0.09)     
0.05 
(0.038)  
[0.011]     
0.041 
(0.054) 
[0.001]      
0.053 
(0.044) 








(0.104)     
-0.025 
(0.141)     
0.031     
(0.116)      
0.026   
(0.032) 
[0.006]      
0.058 
(0.049) 
[0.013]      
-0.003 
(0.049) 







0.207*   
(0.102)      
0.083 
(0.116)      
0.296 
(0.182)      
0.094** 
(.047) 
  [0.021]    
0.068 
(0.049) 
[0.016]     
0.113 
(0.069) 








(0.082)      
0.088 
(0.134)      
0.091 
(0.09)      
0.105** 
(0.038) 
 [0.024]     
0.144** 
(0.052) 
[0.033]      
0.075 
(0.051) 








(0.084      
0.258** 
(0.092)      
0.146 
(0.107)      
0.102** 
(0.033) 
 [0.023]     
0.175** 
(0.043) 
[0.039]      
0.048 
(0.045) 








(0.103)      
0.157 
(0.112)      
0.102 
(0.141)      
0.016 
(0.034) 
[0.004]      
0.068 
(0.063) 
[0.016]      
-0.021 
(0.049) 








(0.11)     
-0.026 
(0.14)     
0.026 
(0.129)      
0.003 
(0.041) 
[0.001]      
0.045 
(0.065) 
[0.01]      
-0.028 
(0.043) 








(0.087)     
-0.061 
(0.096    
-0.023 
(0.143)     
-0.003 
(0.04)  
[-0.001]    
0.037 
(0.056) 
 [0.008]     
-0.034 
(0.049) 








(0.085)      
0.314**    
(0.121)      
0.028 
(0.106)      
0.072   
(0.027) 
[0.016]     
0.18*** 
(0.042) 
 [0.04]     
-0.011 
(0.044) 











(0.114)    
0.239*   
(0.144)      
0.085 
(0.141)      
0.059 
(0.033 
 [0.013]     
0.112** 
(0.054) 
[0.026]      
0.014 
(0.048) 








(0.111)      
0.115 
(0.153)      
0.09 
(0.121)      
0.045 
(0.039) 
[0.01]      
0.097* 
(0.053) 
[0.022]      
0.003 
(0.044) 








(0.104)      
0.139 
(0.138)      
0.171 

















(0.104)      
0.16 
(0.105)      
0.123 

















(0.093)     
0.065 
(0.085)      
0.041 









[0.029]      
Entries in Column (1)-(3) represent the estimated coefficients and standard errors from an ordinary least 
squares regression.  Entries columns (4)-(6) represent the estimated coefficient, standard errors, and 
marginal effects from a logit model. Other covariates include dummy variables for age, region, month of 
birth, sex, a cubic quarter of birth trend, race, and ethnicity. Standard errors are clustered on year of 
birth/year of survey cohorts to allow for within group correlation.  
*      Significant at .10 level    **    Significant at .05 level   ***  Significant at .001 level 
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Table 33 
Estimates for Educational Attainment, Adults aged 55 to 90, 1982 to 2002 NHIS 
 
Parameter estimates (standard errors) [Marginal Effect] 






































































(0.137)      
0.242 
(0.204)      
0.022 
(0.177)      
0.049   
(0.067) 
 [0.011]  
0.191* 
(0.106) 
[0.043]      
-0.045 
(0.084) 








(0.263)      
0.164 
(0.183)      
0.185 
(0.367)      
0.005 
(0.056) 
 [0.001]    
0.087 
(0.079) 
[0.02]      
-0.056 
(0.066) 








(0.092)      
-0.02 
(0.175)     
0.053 
(0.149)      
-0.055 
(0.049) 
[-0.013]     
-0.145* 
(0.083) 
[-0.034]    
0.01 
(0.088) 








(0.144)      
0.009 
(0.19)      
0.03 
(0.212)      
-0.057 
(0.061) 
[-0.013]    
0.044 
(0.101) 











(0.132)      
0.047 
(0.141)      
0.146 
(0.181)      
0.009 
(0.061) 
[0.002]      
-0.023 
(0.089) 
 [-0.005]    
0.032 
(0.079) 








(0.135)     
-0.178 
(0.239)     
-0.18* 






[0.011]      
-0.017 
(0.07) 








(0.133)    
0.08 
(0.143)      
-0.282 

















(0.189)     
-0.38 
(0.13)     
0.138 






[-0.031]     
-0.064 
(0.11) 








(0.134)      
0.035 
(0.123)      
0.016 






[0.02]    
0.022 
(0.084) 
 [0.005]     
Entries in Column (1)-(3) represent the estimated coefficients and standard errors from an ordinary least 
squares regression.  Entries columns (4)-(6) represent the estimated coefficient, standard errors, and 
marginal effects from a logit model.  Other covariates include dummy variables for age, region, month 
of birth, sex, a cubic quarter of birth trend, race, and ethnicity. Standard errors are clustered on year of 
birth/year of survey cohorts to allow for within group correlation.  
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Figure 3 – Vioxx and Celebrex Prescriptions by Year 














































































































 Figure 5 – Activity Limitation Status by Vioxx Prescription Use 
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Figure 7 – Labor Supply by Vioxx Prescription Status 
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Figure 10 – Estimated of In-Utero Flu Exposure on Coronary Heart Disease by Age, 






























Figure 11 – Highest Grade Completed by Year of Birth 
































Figure 12 – Percent Graduating High School by Year of Birth 
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